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As the presence of hypervirulent Klebsiella pneumoniae (hvKP) has not been studied 
in the United Arab Emirates (UAE), the aim was to determine its rate among 
bloodstream isolates collected in a tertiary care hospital during a two-year period. K. 
pneumoniae blood isolates of 125 individual patients from Tawam Hospital, Al Ain in 
2014-2015 were investigated. Clinical data on patients’ demographics and underlying 
medical conditions were collected. Speciation was carried out by VITEK 2, 
antimicrobial susceptibility was determined by disc diffusion and for colistin by 
microdilution. Hypermucoviscosity was assessed by string test. Genetic markers of 
hypervirulence (iucA, rmpA, rmpA2), K1 and K2 serotype-specific alleles, and 
carbapenemase genes were detected by PCR. HvKP isolates were compared by PFGE 
and by MLST and the localisation of rmpA was confirmed by hybridization. Fischer’s 
exact test was used to calculate correlations between categorical variables. Of the 125 
isolates 13 (10.4%) iucA and rmpA/rmpA2 positive strains were identified and were 
considered hvKP. Eight of them were string test positive. They were distributed among 
CC23 - serotype K1 (6, PFGE similarity >80%), ST65 – K2 (1), ST380 – K2 (2), ST86 
– K2 (1), ST36 (1) and ST714 (2), respectively. While the majority of them were 
susceptible to most antibiotics tested, one K. pneumoniae ST23 was multi-drug 
resistant and produced a new allele of VIM carbapenemase. hvKP strains were more 
likely to be isolated from diabetic than from non-diabetic patients (P=0.001) and from 
patients who have not received prior antimicrobial therapy (P=0.0208). A further 11 
iucA positive isolates were rmpA/rmpA2 and string test negative. Ten of these strains 
produced OXA-232 carbapenemase and were extremely drug resistant (XDR). These 
isolates belonged to K. pneumoniae ST231. The results surmise that while members 
of this latter, carbapenem resistant group may not fully qualify as hvKP, yet, they carry 
the potential to develop into hvKP by acquiring the plasmid-coded exopolysaccharide 
synthesis regulator, rmpA. An alarming rate (>10%) of hvKP was demonstrated among 
bloodstream isolates studied with the presence of a carbapenem resistant, hyperviscous 
phenotype hvKP ST23 isolate producing a novel VIM-carbapenemase.  
Keywords: Hypervirulent Klebsiella pneumoniae (hvKP), Hypermucoviscosity, 






Title and Abstract (in Arabic) 
 
دراسة سالالت الكلبسية الرئوية الضارية المعزولة من مجرى الدم في االمارات العربية 
 المتحدة
 الملخص
شديدة   (hvKP)دراسات كافية لسالالت بكتيريا الكلبسية الرئوية الضاريةنظًرا لعدم وجود 
هو تحديد معدالته بين العينات المعزولة  الهدففي دولة اإلمارات العربية المتحدة، كان  الضراوة
 .من مجرى الدم التي تم جمعها في مستشفى قطاع الصحة الثالث خالل فترة عامين
مريًضا في  125االلتهاب الرئوي المعزولة من  عينة من بكتيريا 125يعادل تم فحص ما 
تم جمع البيانات السريرية والحاالت الطبية  .2015-2014مستشفى توام، العين في الفترة ما بين 
، وتم تحديد القابلية للمضادات VITEK 2تم تعريف البكتيريا عن طريق ال  .األساسية للمرضى
كوليستين فتم اختباره عن طريق ، اما بالنسبة لمضاد ال disc diffusion ال الحيوية عن طريق
تم الكشف عن عالمات . (Stringتم تقييم فرط المخاطية عن طريق اختبارال ) .التخفيف الجزئي
الخاصة  K2 و K1 التم تعيين ،  (iucA, rmpA, rmpA2)جينية لتحديد مدى ضراوة العينات 
تمت مقارنة عينات  . PCRال  بواسطة  carbapenemasesال  يناتبالنمط المصلي، وكذلك ج
بواسطة ال  rmpA تم تحديد وجود جين ال ، MLSTو PFGE تقنية ال بواسطة hvKP ال
hybridization . تم استخدام اختبار فيشر الدقيق لحساب االرتباطات بين المتغيرات الفئوية  
 .للفئات المختلفه
 ,iucAعينة موجبة لجينات ) (%10.4) 13 تم ايجادعينة،  125بناء على دراسة ال 
rmpA/rmpA2) ( واعتبرت عينات شديدة الضراوةhvKP.)  ثمانية منهم كانت ايجابية الختبار
 K2 (1), ST380 -K1 (6), ST65  -CC23  االنماط التالية تم توزيعها بين( وstringال )
 ), ST36 (1) ST714 (2)K2 (1 -K2 (2), ST86  - على الرغم من أن معظم  .على التوالي
كانوا شديدي الحساسية لمعظم المضادات الحيوية التي تم اختبارها، إال أن ( hvKPعينات ال )
وأنتج نوعا جديدًا من  لعدة مضاداتكان مقاوًما  ST23 أحد أنواع هذه البكتيريا المنتمية لنمط ال
أكثر من مرض السكري مقارنةً بالمرضى غير  hvKP سالالت التم عزل  (.VIMجين ال )
وكذلك من المرضى الذين لم يتلقوا اي عالج سابق بالمضادات  (P=0.001المصابين بالسكري )






ولكنها سالبة لكل من جينات  iucAعينة موجبة لجين ال  11كذلك بينت الدراسات ان هناك 
 أنتجت عشر من هذه السالالت جين ال  (.stringلك الختبارال )( وكذrmpA/rmpA2)ال 
OXA-232 ( وكانت مقاومة للغاية لألدويةXDR .)من  الرئوية الكلبسيه تنتمي هذه العينات إلى
نحن نفترض أنه على الرغم من أن أعضاء هذه المجموعة األخيرة، مجموعة ، وST231النمط 
 شديدة الضراوة،  hvKP ال ينتمون الى الساللة الضارية المقاومة للكاربابينم قد  OXA-232ال 
 rmpAمن خالل الحصول على جين ال  إال أنهم يحملون القدرة على التطور إلى هذه الساللة
 المنقول بواسطة البالزميدات. 
 الضراوه الشديدةالسالالت الضارية  من (%10<) تم إثبات وجود معدل ينذر بالخطر
(hvKP )المعزولة من مجرى الدم التي تمت دراستها مع وجود عينة للنمط  بين العيناتST23 
  .VIMمن جين ال  المقاوم للكاربابينيم، والمنتج لنوع جديد
، فرط المخاطية، اختبارال  (hvKP)بكتيريا الكلبسية الرئوية الضارية :مفاهيم البحث الرئيسية
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Chapter 1: Introduction 
 
1.1 Enterobacteriaceae  
The Enterobacteriaceae family is the largest heterogeneous group of medically 
important Gram-negative bacteria. Currently it contains 50 genera and dozens of 
named species as well as subspecies. Initially, they were classified according to their 
biochemical properties, antigenic structure and subsequently by DNA-DNA 
hybridization and 16S rRNA gene sequencing. Most members of the family are 
ubiquitous organisms besides their human and animal hosts as part of the normal flora, 
are also found in soil and water (Murray, 2013).  
They are Gram-negative, non-spore straight rods relatively small in size (0.3 
to 0.3 to 1.0 x 1.0 to 6.0 μm). Some genera are motile by means of peritrichous flagella, 
meanwhile others are non-motile (Murray, 2013). 
Members of Enterobacteriaceae family exhibit varying levels of 
pathogenicity. Those that are members of the normal flora can cause infections only if 
displaced to other body-sites (e.g. Escherichia coli from the gut to the urinary tract). 
Others are strict pathogens, like members of the Salmonella genus, while several of 
them cause mainly opportunistic infections, i.e. exclusively in patients with 
compromised defense systems (e.g. Serratia marcescens). The subject of the thesis is 
an important member of this family belonging to the genus Klebsiella, i.e. K. 








1.2 The genus Klebsiella and Klebsiella pneumoniae 
The intensive recent research directed towards the genus Klebsiella has 
resulted in considerable fluidity in its taxonomy that is far from a complete consensus. 
According to the Taxonomy Browser of the NCBI the genus contains several species 
and subspecies of which the most important ones are K. pneumoniae, K. oxytoca, K. 
rhinoscleromatis, K. quasipneumoniae, and K. variicola (Wyres and Holt, 2016). K. 
pneumoniae are fermentive bacteria which produce lysine decarboxylase but not 
ornithine decarboxylase and are generally positive in the Voges-Proskauer test 
(Enjalbert et al., 1979). They are non-motile, facultative anaerobes and it can grow 
rapidly on variety of selective and non-selective media.  The colony appearance on the 
media is typically large, mucoid (wet, heaped, viscous colonies) due to a prominent 
capsule (Murray, 2013; Podschun and Ullmann, 1998).   
It was first described by the German microbiologist Edwin Klebs (1834 – 1913) 
in 1875 while examining the airways of patients who died due to pneumonia. 
Eventually, the species was formally described by Carl Friedlander in 1882 and the 
organism was named "Klebsiella pneumoniae" by Trevisan in 1885 (Etymologia: 
Klebsiella et al., 2010) (Friedländer, 1882). To honor Friedlander’s contribution, the 
multilobar bronchopneumonia often leading to pulmonary abscesses and lung 
necrosis, typically seen in cases caused by K. pneumoniae used to be called 
“Friedlander pneumonia”.  Currently, K. pneumonia is one of the important causes of 








1.3 The pathogenicity of Klebsiella pneumoniae  
K. pneumoniae is responsible for numerous infections within hospitals, long 
term care facilities as well as in the communities worldwide and (Carpenter, 1990).  It 
is often described as an opportunistic pathogen as, nowadays, most infections are seen 
in hospitals among inpatients with varying degrees of immunocompromisation.  It 
should be kept in mind, however, that although it is part of the normal flora, under 
certain circumstances, they have the ability to cause severe illnesses, such as 
pneumoniae or bacteremia, meningitis and other infections in non-
immunocompromised people, as well (Figure 1) (Murray, 2013).   
 







Klebsiella spp. are ubiquitous in nature, in environments, such as in water, 
sewage, soil and plants (Morrow et al., 1978; Wyres and Holt, 2018).  In addition to 
the hospital settings and medical devices, in association with the human host, K. 
pneumoniae is usually found in the mouth, skin and intestines. Generally, the 
colonization of the GI tract by K. pneumoniae takes place before the development of 
nosocomial infections (Podschun and Ullmann, 1998). It has been found that K. 
pneumoniae biofilms that appear on medical devices (e.g., catheters and endotracheal 
tubes) plays a significant role in infection of catheterized patients (Schroll et al., 2010). 
Studies by Jagnow and Clegg (2003) showed that nosocomial infections caused by K. 
pneumoniae have the tendency to be persistent due to the presence of K. pneumoniae 
biofilms in-vivo which protects the bacteria from attacks of the host immune responses 
and from antibiotics (Jagnow and Clegg, 2003).  In addition, nosocomial isolates of K. 
pneumoniae often exhibit multidrug-resistance (Paterson et al., 2004; Munoz-Price et 
al., 2013).  Such resistance factors considerably increase the ability of these organisms 
to spread widely and rapidly which will often lead to nosocomial outbreaks within the 
hospital, making it one of the most common organisms causing such epidemics (Kuhn 
et al., 1993). 
Taken together, K. pneumoniae is a globally encountered pathogen that 
remains a significant cause of both community-acquired and healthcare-associated 
infections, including bacteremia. Currently, with the increase of hospitalized and 
immunocompromised patients, most infections are encountered nosocomially among 
individuals suffering from various underlying conditions (Shon et al., 2013). 
There are two major factors that make K. pneumoniae one of the most 






 its broad pathogenic potential and  
 its proclivity to become resistant to antibiotics. 
1.3.1 Virulence factors 
The disease-causing capacity of an organism, in relation to a specific host, is 
called “pathogenicity”, while, its quantitative expression is called “virulence”. Both 
terms refer to the capacity of a microorganism to replicate and disseminate and cause 
disease or kill the host. Virulence factors are molecules and cells structure components 
with functions essential in the pathogen–host interaction during the process of 
infection.  These traits enhance the ability of bacteria to cause pathological changes 
within the host (Baer and Harold, 1956; Murray, 2013; Clegg et al., 1992; Rosen et 
al., 2008). 
K. pneumoniae exhibit complex interactions with the host, and hence, a number 
of bacterial factors have been identified that contribute to the pathogenesis of these 
















Table 1: Virulence factors involved in the pathogenesis of Klebsiella pneumoniae 
(Clegg and Murphy, 2016) 
 
1.3.1.1 Capsular antigens 
Two major components are expressed on the surface that are essential for the 
virulence of K. pneumoniae: the capsular polysaccharide (CPS; the K antigen) and the 
lipopolysaccharide (LPS; the O antigen) (Follador et al., 2016) K. pneumoniae 
contains a thick capsule layer surrounding the bacterium (160 nm) that is generally 
considered an important factor in its pathogenicity (Figure 3). 
Factor Function 
Capsule  
Inhibit and evade phagocytosis by host cells, induces dendritic 
cell maturation, neutralizes antibacterial activity of host 
defense 
LPS  O antigen provides serum resistance 
Siderophore  
Scavenge essential iron for survival, hypermucoviscous 
phenotypes have been linked to increased iron-binding activity 
Urease 
 Limited role in precipitation of inorganic salts leading to 
catheter encrustation 
Type 1 fimbriae  
Involved in the formation of intracellular bacterial 
communities 
Type 3 fimbriae  
Important for biofilm formation on biotic and abiotic surfaces, 
role in biofilm formation on urinary catheters in vivo remains 
to be elucidated 
Biofilm 
formation  
Formation promotes resistance to host killing and 
antimicrobials, experimentally shown to be facilitated in part 
by fimbriae and capsule 
Antibiotic 
resistance  






               
Figure 3: Cell wall structure of Enterobacteriaceae (Murray, 2013) 
 
For a bacterium to cause infections, the first step is to enter and colonize the 
host and in this the capsule plays important roles. The capsular material forms a thick 
bundle of fibrillous structures that covers the bacterial surface. The capsule is strongly 
antiphagocytic, protecting the bacteria from phagocytosis and from bactericidal serum 
factors. Furthermore, it can act as a barrier to toxic hydrophobic molecules, like 
detergents (Murray, 2013).     
Strains of K. pneumoniae can express several antigenically distinct capsules 
and some are considered to be associated with increased virulence potential. The 
capsule antigens K1, K2, K4 and K5 are mainly associated with high virulence degree 
(Kato, 1983).  The degree of virulence conferred by a particular K antigen might be 
connected to the expression of type 1 fimbriae (a mannose receptor-specific adhesin) 






The genes responsible for the production of capsules by K. pneumoniae were 
originally designated as cps gene cluster and were mapped close to his on the bacterial 
chromosome (Clegg and Murphy, 2016). It has been discovered by cloning of the cps 
cluster that the genes are approximately 15kb of DNA and has all the determinants 
which are necessary to define the serotype of a strain (Clegg and Murphy, 2016). The 
studies showed that three alleles of a different gene named rmpA/A2 have been 
described to play a role in the activation of cps-gene expression (Cheng et al., 2010; 
Lai et al., 2003).  
The alleles vary between serotypes and the geographic region of the isolates. 
Two of the alleles are plasmid encoded and the third one is chromosomal. Over 
production of rmpA leads to a hypermucous phenotype in K. pneumoniae and to the 
increase in expression of the transcriptional fusions of cps-promoter regions (Lai et 
al., 2003). The transcription of rmpA is inhibited by not only the Fur protein but also 
by other genes associated with iron-acquisition systems in K. pneumoniae (Lin et al., 
2011). For that reason, the concentration of available iron in the environment of the 
Klebsiella strains can play a major role in the expression of the virulence gene, 
including the amount of capsule produced by clinical isolates. The studies showed that 
K1 serotypes of K. pneumoniae are associated with causing severe disseminated 
infections. The mucoviscosity-associated gene (magA) was found to be part of the cps-
gene cluster in these isolates and necessary for K1 biosynthesis (Fang et al., 2010). 
Earlier, this gene has been used to identify, by polymerase chain reaction (PCR), K1-
positive strains, but recently a similar allele was found in other K-serotypes (Fang et 






The wzy and wzi genes are present in all K types, but each one of them has a 
high level of variable sequence between distinct K types. Based on that, wzy-targeting 
PCR assays have been set to identify K1, K2, K3, K5, K20, K54 and K57 (Turton et 
al., 2010; Fevre et al., 2011), and by wzi sequencing one can reveal the K types of 
most clinical K. pneumoniae isolates (Brisse et al., 2013).  
Generally, the most virulent strains of K. pneumoniae produce a capsule made 
of saccharides that do not facilitate binding to phagocytic cells and hence are more 
resistant to phagocytosis (Clegg and Murphy, 2016).  
1.3.1.2 Lipopolysaccharide (LPS)  
Similarly to other members of the family Enterobacteriaceae, the 
lipopolysaccharides (LPSs) of K. pneumoniae consist of three structural domains 
shown on Figure 3, (i) the hydrophobic lipid A, which is  a major component of the 
outer leaflet of the Gram-negative outer membrane and is responsible for the endotoxin 
activity and is an important virulence factor, (ii) the core oligosaccharide, which is 
linked to lipid A and provides the attachment site for (iii) the long chain polysaccharide 
(O antigen; O chain) (Follador et al., 2016; Murray, 2013). 
Beyond the endotoxic nature of LPS, the O antigen also contributes 
significantly to the virulence of K. pneumoniae. The presence of cell wall receptors 
enables K. pneumoniae to attach to the host cell. Correspondingly, LPS have been 
implicated in the pathogenesis of K. pneumoniae causing community-acquired 
pyogenic liver abscess (PLA) (Tomas et al., 1997). 
It has been shown in different studies that K. pneumoniae O-antigen prevents the 






contributes to bacterial resistance against complement-mediated killing (Merino et al., 
2000).  
1.3.1.3 Pili (fimbriae) and adhesion 
Pili or fimbriae are hairlike structures, 10 μm long and have a diameter of 1 to 
11 nm (Jones and Isaacson, 1983). They are composed of polymeric globular protein 
subunits (pilin) and are protruding from the surface of the bacteria (Murray, 2013).  As 
an adherence factor, fimbriae are important determinant of colonization.   
The three K. pneumoniae fimbrial adhesins that have been described in detail 
are types 1 and 3 fimbriae and the Kpc fimbriae (Clegg et al., 2011; Wu et al., 2010). 
Type 1 fimbriae, also known as mannose-sensitive fimbriae, because of their capability 
to bind soluble mannose as a competitive inhibitor to binding, are usually encoded by 
the fim gene cluster.  Type 3 fimbriae are encoded by the mrk-gene cluster and can be 
present in K.  pneumoniae on a plasmid and/or a chromosomal gene cluster (Clegg and 
Murphy, 2016). It has been noted that mrkA is the major structural component of the 
fimbrial shaft and that mrkD helps to facilitate binding to extracellular- matrix proteins 
and act as the fimbrial adhesion (Clegg and Murphy, 2016).   
The studies showed that the Kpc fimbriae are most frequently associated with 
K1-positive strains of K. pneumoniae causing disseminated pyogenic infections (Wu 
et al., 2010). The production of these fimbriae is mediated by the kpcABCD gene 
cluster, although the conditions for optimal expression of these genes have not been 






The other type of Klebsiella spp. adhesin is the plasmid encoded CF29K. This 
fimbrial type is characterized by aggregative adhesion to the intestinal cell lines (Joly, 
1992).   
1.3.1.4 Serum resistance 
The bactericidal effect of serum is one of the first line of defense by the host 
against invading microorganism. Serum resistance represented by activation of 
complement proteins. Complement components are activated in a cascade manner 
through 3 different pathways of activation namely classical, alternative or by the lectin 
pathway. The complement system plays a vital role in humoral defense against 
microbial pathogens. The serum bactericidal system has a very important role which 
is to prevent microorganisms from invading and persisting in the blood (Ramm et al., 
1983; Taylor, 1983; Old and Adegbola, 1985; Doorduijn et al., 2016).  In a study of 
Gharrah et al., 2017 serum resistance was one of the pathogenicity factors of Klebsiella 
and serum resistance was an indication of the higher pathogenicity (Gharrah et al., 
2017). Interestingly, studies found relationship between ESBL production and serum 
resistance showing that serum resistance was elevated in K. pneumoniae ESBL 
producer than non-ESBL producing K. pneumoniae (Lin et al., 2016).  
1.3.1.5 Iron acquisition 
Iron is an essential factor in bacterial growth but the availability of free ferric 
iron (Fe3+) in the host is usually extremely low. Consequently, pathogens, such as K. 
pneumoniae should be equipped to secure their iron supply from the host. This is 
achieved by a variety of mechanisms, most commonly either through ABC transporters 






siderophores (Bullen et al., 1978; Khimji and Miles, 1978; Griffiths, 1988; Behnsen 
and Raffatellu. 2016; Ellermann and Arthur, 2017).  Although the presence of 
siderophores are likely to be essential in all systemic infections, their role was mostly 
studied in a set of K. pneumoniae strains, called hypervirulent K. pneumoniae. 
Approximately a dozen different systems have been identified that play a role 
in supplying iron to K. pneumoniae (Liu et al., 2014) of which the siderophore-based 
systems are the most important (Table 2). 
Table 2: The most common iron acquisition systems of K. pneumoniae (simplified 
from Liu et al., 2018) 
System Name Genes 
Kfu ABC transporter kfuABC 
Fep-Ent Enterochelin 
fepA-entD, fes-entF, 
fepDGC, ybdA, febB, 
entCEBA 
IroA Salmochelin iroN, iroBCDN 
Iuc Aerobactin iucABCD-iutA 




In clinical isolates these siderophore genes can be present in different 
combinations. Mutants lacking them are attenuated (Clegg and Murphy, 2016). A 
study of more than thirty strains of 23 different serotypes of K. pneumoniae showed 
that the siderophore enterochelin was the predominant iron-salvaging-system 
compound produced in urinary tract infections (Tarkkanen et al., 1992). This was in 
contrast to bacteremic strains, mainly K1 and K2 serotypes, in which aerobactin was 
correlated to virulence. Some, particularly the aerobactin system is highly 






1.3.2 Hypervirulent (Hypermucoviscous) Klebsiella pneumoniae 
Lately, the majority of infections caused by ‘classic’ K. pneumoniae (cKP) 
occurred in hospitals and long-term care facilities.  Recently, however, a new type of 
infection emerged caused by more or a less distinct group of strains, initially called 
hypermucovicous, lately named hypervirulent K. pneumoniae (hvKP). Often, these 
infections were community-acquired, invasive, life-threatening ones; not infrequently 
with unusual locations among young, otherwise healthy individuals, i.e. showing a 
real, instead of opportunistic pathogenic potential of the species.  The first cases were 
recorded in the Asian Pacific Rim including Taiwan, Korea, Vietnam and Japan.  In 
the mid-1980s and 1990s, Taiwan has recorded patients with no previous history of 
hepatobiliary disease presenting with community-acquired pyogenic liver abscesses 
(CA-PLA) (Cheng et al., 1991; Wang et al., 1998; Lin et al., 2018). The hvKP 
infections were seen in all age groups and despite the fact that some patients have co-
morbidities, it is commonly noted in younger and healthy patients and as a result, hvKP 
will cause infection in various sites in the body such as abdominal disease, splenic 
abscess, thoracic disease (pneumonia), meningitis and other CNS infections, UTI and 
bacteremia.   
1.3.2.1 Hypermucoviscous Klebsiella pneumoniae 
Most hvKP, when growing on blood agar (BA), appear to have excess amount 
of mucus, even more than the regular amount causing “mucoid” appearance of the 
colonies of the species, i.e. these colonies are hypermucoviscous. Such strains can be 
identified by the ‘string test’.  The formation of a viscous string of > 5 mm in length 
using inoculation loop and stretching the bacterial colonies is considered positive as 







Figure 4: Positive ‘string test’ on a hypervirulent strain of Klebsiella pneumoniae 
(Shon et al., 2013) 
 
1.3.2.2 Hypervirulent Klebsiella pneumoniae 
Several genes have been implicated to contribute to the virulence of K. 
pneumoniae, like those associated with iron uptake (e.g. iucA, iutA, ybtS, entB, kfuB), 
fimbria formation (e.g. fimH, mrkD) and in particular the formation and 
hyperproduction of capsule (e.g. magA, wabG, wcaG, rmpA, rmpA2) (Fang et al., 
2007; Turton et al., 2010; Candan and Aksoz, 2015). While it is still debated what are 
the clear criteria of hypervirulence, there are certain factors that show a close 
association with it. 
As the initial marker of hypervirulence was linked to the highly viscous 
character of the strains, extensive studies were performed to identify the capsular 
serotypes playing unique role in facilitating it. There are nearly 80 capsular serotypes 
including K1, K2, K5, K16, K20, K54, K57 which were implicated to facilitate 
virulence in hvKP strains (Chuang et al., 2006; Pan et al., 2008; Cheng et al., 2012). 






encountered among hvKp. In one study, among the 67 K. pneumoniae that were 
isolated from the community in Canada, Denmark, Norway, South Africa, Taiwan and 
the United States in the period of 1996 to 2012 as 30 strains appeared to be hvKP by 
being hypermucoviscous. The majority (28/30) belonged to K1 capsule serotype and 
the other two belonged to K2 (Cheng et al., 2012). In another study in China 230 strains 
were isolates from pneumonia, intra-abdominal infection and bloodstream infections. 
37.8% of the isolates were hvKP, out of which, 33.3% were K1 and 17.2% were K2 
(Wang et al., 2016). 
In a separate project (Yinjuan, 2017), a total of 84 hyperviscous isolates were 
tested for the capsular antigen and the following were identified: K1 (23.8%, 20/84), 
K2 (42.9%, 36/84), K5 (2.4%, 2/84), K20 (4.8%, 4/84) and K57 (9.6%, 8/84). In 
Singapore and Taiwan also capsular serotypes K1 and K2 dominated isolates of K. 
pneumoniae causing liver abscess. A total of 73 isolates were serotyped and the most 
predominant serotype K1 accounting for (34/73; 46.6%), K2 (15/73; 20.5%) and non-
K1/K2 (24/73; 32.9%) (Yeh et al., 2007). Through their attempt to investigate gene 
association with capsular serotype it was found that magA was restricted to, and 
present in all 34 K1 isolates, while all the 73 hyperviscous isolates were positive for 
rmpA (Yeh et al., 2007).  Severe complications of hvKP bacteremia is common. In a 
Chinese study (Yeh et al., 2010; Hsu et al., 2011). Studying 285 blood culture isolates 
the hypermucoviscous phenotype was seen in 24% of these isolates, the prevalence of 
K1 and K2 were 40.6% and 31.9%, respectively. rmpA and magA were strongly 
associated with viscous phenotype (Yeh et al., 2010; Hsu et al., 2011). 
The rmpA/rmpA2 genes (regulator of the mucoid phenotype) mediate the 






chromosomally and plasmid encoded. Once on a plasmid, its size is 180–220 kb which 
may also code for other factors that may be involved in virulence. (Hsu et al., 2011) 
Once again, a very close association was found between these regulators and the hvKP 
character (Yeh et al., 2010; Hsu et al., 2011).  
These capsule types may also be present in strains colonizing the intestinal 
tract. Investigating stool specimens from 954 healthy Chinese adults who were 
residents of Taiwan, Hong Kong or China or were living abroad in Japan, Thailand, 
Malaysia, Singapore and Vietnam K. pneumoniae was isolated from 592 individuals 
and of them, 4% of the strains carried K1, while 2% expressed K2 capsular types 
(Brisse et al., 2009).   Similar results were obtained in a separate study in South Korea 
showing that of the 248 K. pneumoniae strains isolated from stool samples of healthy 
carriers 4.9% carried the K1 capsule type (Cheng et al., 2012). 
In China, (Yinjuan, 2017): nearly all (95.2%) K1, K2, K5, K20 and K57 
isolates with hypermucoviscosity phenotype were positive for rmpA. Furthermore, this 
study could also show a close association between mrkD and the K2 capsular type 
isolates (Yinjuan, 2017). A similarly important finding of this study was that 
aerobactin-coding genes iucA was present in 95.1% of the hyperviscous strains and 
only in 41.1% of HMKP of the non-hyperviscous isolates. 
Actually, the association with iron acquisition mechanisms were shown in K2 
capsule type strains, too, as they produced more iron-acquisition factors than there 
“classic”, cKP counterparts (Russo et al., 2011). Indeed, and increasing body of 
evidences suggest that beyond surface properties, as capsular types, iron acquisition 
plays a central role in increasing the pathogenic potential of K. pneumoniae to the 






biosynthesis of siderophore aerobactin, coded by the iuc gene, and that of salmochelin 
(iro) are closely linked to hypervirulent K. pneumoniae clones causing invasive 
community-associated infections, such as liver abscess and pneumonia. It was also 
found that when examining the genome of 2503 K. pneumoniae isolates not known to 
be hypervirulent, iuc was detected in 8.7% and iro was presents in 7.2%, only (Russo 
et al., 2015). 
In another study, among K. pneumoniae causing severe community-acquired 
(CA) infections, such as pyogenic liver abscess, pneumoniae and meningitis of 
neonates, i.e. features of hvKP, the presence of acquired siderophores genes was also 
common (Holt et al., 2015).  
A number of other factors may also contribute to the colonization and invasion 
across the intestinal barrier such as the LPS, Outer Membrane Protein (OMP), genes 
associate with the intestinal colonization, but they seem to be less specific to the hvKP 
character than rmpA/A2 and iuc (Struve et al., 2003; Ma et al., 2005; Hsieh et al., 2008; 
Wu et al., 2011). The metabolism of allantoin is a process by which bacteria can obtain 
carbon and nitrogen from their environment (Paczosa and Mecsas, 2016). In a search 
of K. pneumoniae genes whose transcription was upregulated in HV K. pneumoniae 
strains compared to classical strains, an operon containing genes involved in allantoin 
metabolism was identified. The deletion of allS, an activator of this operon, resulted 
in an HV K. pneumoniae strain with significantly reduced virulence in an intragastric 
model of infection (Chou et al., 2004). A study by Yu et al., 2008, found that allS was 
present in 100% of HV K. pneumoniae isolates from Taiwan but it was absent in K2 
isolates and non-K1/K2 isolates from patient blood or liver samples (Yu et al., 2008).  






The most predominant sequence typing strongly associated with hvKP is sequence 
type (ST) 23 and that is linked with K1 capsular serotype and liver abscess (Pitt et al., 
2007; Peck et al., 2008; Decre et al., 2011).  Furthermore, ST86, ST375 and ST380 
are mainly associated with K2 serotype (Jung, 2013).  A study in South Korea showed 
that, nearly all (94.7%) of the K1 capsule type strains (representing 4.9% of all K. 
pneumoniae isolated from fecal samples of healthy individuals) belonged to ST23 
(Cheng et al., 2012). 
1.3.3 Bloodstream infections caused by Klebsiella pneumoniae 
K. pneumoniae, just like E. coli, has been implicated in practically every kind 
of extraintestinal infections including urinary tract infections, tissue infections and 
pulmonary infections (Bennett et al., 1995; Lye et al., 1992; Siu et al., 2012). In South 
America, Klebsiella pneumoniae represents the third most prevalent pathogen isolated 
from the respiratory tract of patients with pneumonia and it represents 12% of all 
pathogens isolated (Marra et al., 2006). While these focal or more or less localized 
infections can have serious consequences on their own, they can also be the source of 
bloodstream infections (BSI) (Fader and Davis, 1980).  
The status of the host defense contributes in two ways to the development of 
BSIs. On one hand, the initial focal infection is more likely to develop in patients with 
predisposing conditions and weaknesses (e.g. catheterized patients, ventilated patients, 
immunosuppressed patients). On the other hand, weak defenses decrease the chances 
to control the infection locally, and hence, increases the chances that the infection 






Seeing an increase number of patients with decreased immunocompetence, 
either due to their comorbidities (e.g. malignancies) or to the medical interventions, 
the number of BSIs caused by K. pneumoniae continue to increase worldwide 
(Podschun et al., 2001). Actually, K. pneumoniae considered as the second most 
common pathogen in the family Enterobacteriaceae which causes BSIs (Podschun et 
al., 2001). Recently, international published observational study found that among the 
1,156 ICU patients with BSI from all over the world 57.6% were caused by Gram-
negative bacteria of which 38% was K. pneumoniae (Russotto et al., 2015).   
1.3.3.1 Bloodstream infections in patients with malignancy 
Bloodstream infections (BSI) are a major cause of critical complications in 
patients with cancer and are directly connected with extended hospital stay, expensive 
healthcare costs and high risk of morbidity and mortality. The overall rate of mortality 
of BSI in cancer patients is reported to be 25–32%.  Bacteria represent the most 
common cause (Obeng-Nkrumah et al., 2015).  
Recently, a shift from Gram-positive to Gram-negative organisms has been 
acknowledged in the etiology of BSI with considerable variation according to 
geographic location (Munoz-Price et al., 2013). It has been found that Gram-negative 
bacteria were the most frequent contributory agents isolated in BSIs in malignant 
patients. It has been noticed that K. pneumoniae, E. coli, and P. aeruginosa are the 
main microorganisms involved in BSIs and are the same microorganisms which are 
responsible for bacteremia as reported in Europe (Lon et al., 2019). 
In a recent study in Mexico, it was found that 14% of patients with solid tumors 






with solid malignancies per year. In the United States, the incidence of sepsis in 
patients with cancer in a similar setting is about 16.4 (including hematology patients) 
(Lon et al., 2019).  
The role of the compromised defense capacities due to malignancies have been 
well-illustrated by a study from Taiwan. A total of 158 cases of K. pneumoniae 
bacteremia were analyzed. 40.5% of them were considered nosocomial and the most 
common underlying disease was neoplasia (53%), followed by hepatobiliary diseases 
(22%) and diabetes mellitus (n = 8,12 %) (Chang et al., 2002).  
The mortality rate of K. pneumoniae BSIs varies from 15 to 79% (Xu, et al., 
2018), which is lower if compared to Acinetobacter baumannii BSIs (30 to 84%) but 
higher than Escherichia coli (5 to 22%) (Xu et al., 2018).  
Beyond the actual virulence of the strains, the other major microbial factor that 
impacts the outcome of infections is the resistance to antibiotics (Xu et al., 2018) 
(Kakeya et al., 2016). In Italy, in a recent study on patients with haematological 
malignancies, of the 22 patients colonized with carbapenem resistant K. pneumoniae 
(CRKP) 14 (64%) patients developed bacteremia (Fo et al., 2017). It is noteworthy 
due to the potentially grave consequences as BSI caused by CRKP have become a very 









1.4 Antibiotic resistance of Klebsiella pneumoniae 
Antibiotics resistance, and in particular multi-drug resistance (MDR) became 
a severe, global burden on healthcare. The CDC identified those organisms which 
represent the most urgent threats of antibiotic resistance Table 3 (CDC, 2018). 
Table 3: The categories of urgent threats of antibiotic resistant bacteria (CDC, 2018) 
Category Pathogens 
Urgent Threats 
Clostridium difficile  
Carbapenem-resistant Enterobacteriaceae (CRE)  
Drug-resistant Neisseria gonorrhoeae 
Serious Threats 
Multidrug-resistant Acinetobacter  
Drug-resistant Campylobacter  
Fluconazole-resistant Candida (a fungus)  
ESBL producing Enterobacteriaceae (ESBLs)  
Vancomycin-resistant Enterococcus (VRE)  
Multidrug-resistant Pseudomonas aeruginosa  
Drug-resistant non-typhoidal Salmonella  
Drug-resistant Salmonella Typhi 
Drug-resistant Shigella 
Methicillin-resistant Staphylococcus aureus (MRSA)  
Drug-resistant Streptococcus pneumoniae  
Drug-resistant tuberculosis  
Concerning 
Threats 
Vancomycin-resistant Staphylococcus aureus (VRSA)  
Erythromycin-resistant Group A Streptococcus  
Clindamycin-resistant Group B Streptococcus  
 
It should be noted that Enterobacteriaceae, that includes K. pneumoniae, once 
developing resistance to the most advanced beta-lactams, i.e. carbapenems, are on the 
top of the list. 
Antibiotics are natural products of microorganisms with the role of inhibiting 
the growth of other microorganisms competing for the same niche. This antimicrobial 
activity is being used in medicine, although in most cases the natural products are 






Antibacterial drugs can be either bactericidal or bacteriostatic depending on the 
species and the drug, and in some cases its concentration (Aminov, 2010).  Antibiotics 
are grouped by their mode of action as shown in Table 4 (Murray, 2013; CDC, 2018). 
Table 4: Main mode of action of antibiotics (CDC, 2018) 
Mode of action Examples 
Inhibition of cell wall synthesis ß-lactams, glycopeptides, fosfomycin 
Inhibition of protein synthesis 
aminoglycosides, macrolides, 
tetracyclines, chloramphenicol 
Interference with nucleic acid 
synthesis 
quinolones, fluoroquinolones, rifampin 
Cell membrane disruption polymyxins 
Antimetabolites sulfonamides, trimethoprim 
 
The most common mechanisms by which bacteria could express resistance to 
antibiotics are the enzymatic degradation of the drug, the target alteration of its cellular 
target while preserving its original function, the decrease of its intercellular 
concentration either by decreasing its uptake or by increasing its expulsion by 
upregulating efflux pumps, protecting the target from the access of antibiotics and 
finally overproducing the target. Depending of the species and the drug, any of these 
mechanisms could be part of the natural or the acquired resistance mechanism of 
bacteria (Munita and Arias, 2016). 
Acquired resistance can be the result of mutations or a cell might pick-up 
resistance gene(s) by taking up mobile genetic elements, such as plasmids via 
horizontal gene transfer (HGT) (Read and Woods, 2014; Zaman et al., 2017).  
A broad range of antibiotics can theoretically be used to treat different K. 
pneumoniae infections, i.e. the species does not have natural resistance against them. 






acquired resistance. Therefore, in practice, the list of drugs available to treat K. 
pneumoniae systemic and bloodstream infections (BSI) are often dangerously limited 
and includes ß-lactams, aminoglycosides, tigecycline, fluoroquinolones and 
polymyxins.  Below, a brief discussion will be limited to these groups of drugs, only, 
together with the most common resistance mechanisms against them. 
1.4.1 β-lactam antibiotics 
One of the most common mechanism of antibiotic action is the inhibition of 
cell wall synthesis and β-lactam antibiotics (e.g. penicillins, cephalosporins, 
carbapenems and monobactams) are the most commonly used cell wall active 
antibiotics (Nordmann et al., 2012).  β-lactam antibiotics share a common β-lactam 
ring which is a core structure essential to their bacterial activity. The structures of the 
four groups of ß-lactam antibiotics are shown in Figure 5.  
 
Figure 5: Chemical structures of the main β-lactams and β-lactamase inhibitors 









Penicillins are classified according to their spectra of antimicrobial activity.  
The first group includes the natural penicillin G (benzylpenicillin) and its 
phenoxymethyl derivative, penicillin V, both are effective against β-lactamase non-
producing Gram-positive aerobic organisms including Streptococcus, against 
anaerobes, like Clostridium spp. and against some Gram-negative bacteria, like 
Neisseria meningitidis. Nowadays, penicillinase-resistant penicillins include 
methicillin, nafcillin, oxacillin, cloxacillin and dicloxacillin and they are mainly 
affective against Staphylococcus spp. that produce penicillinase. Ampicillin and 
amoxicillin belong to the third group called aminopenicillins and their antimicrobial 
activity is extended to include Gram-negative organisms, such as Haemophilus 
influenzae, E. coli and Proteus mirabilis.  In the fourth group called ureidopenicillins, 
i.e. cabenicillin, ticarcillin, mezlocillin and piperacillin, are drugs having increased 
activity towards Gram-negative and anærobic organisms including Pseudomonas spp. 
(Jacoby and George, 2010; Nordmann et al., 2010). 
Penicillins, particularly members of the first three groups, and particularly if 
applied without any beta-lactamase inhibitor (see later) have very little role in treating 
K. pneumoniae infections due to their resident β-lactamase (SHV) gene (Livermore et 
al., 2007; Sutaria et al., 2018). 
1.4.1.2 Cephalosporins 
The cephalosporins are derived from 7-amiocephalosporanic acid as the β-
lactam ring is fused with a dihydrothiazine ring (Murray, 2013). They are divided into 






gradually drifted towards Gram-negative cells with somewhat decreasing activity 
against Gram-positive organisms. The 3rd and 4th generation cephalosporins are 
extensively used for the treatment of K. pneumoniae infections (Cole et al., 2015; Lee 
et al., 2015). The 5th generation drugs are active against MRSA due to their increased 
affinity to PBPs.   
The classification of cephalosporins generations in Table 5 is based on the 
general features of antimicrobial activity (Dancer, 2001). 














Escherichia coli, Klebsiella, Proteus, 
Haemophilius influenzae, Moraxella 
catarrhalis. Not as active against gram-
positve organisms as first-generation 
agents.  
Inferrior activity against S. aureus 
compared to cefuroxime but with added 
activity against Bacteroides fragilis and 












aeruginosa, Serratia, Neisseria 
gonorrhoeae, activity for S. aureus, 
Streptococcus pneumoniae, and 
Streptococcus pyogenes comparable to 
first-generation agents.  Activity against 
Bacteroides spp. inferior to that of 
cefoxitin and cefotetan 
Active against Pseudomonas 
Fourth Generation: 
Cefepime 
Comparable to third generation but 




Active against MRSA  








Aztreonam is the main representative of monobactams. They have a narrow 
spectrum activity against aerobic Gram-negative microorganisms without any activity 
against Gram-positive bacteria. While having not been used extensively, lately there 
are likely to experience an increased importance of aztreonam, as this is the only group 
of beta-lactams that are resistant to metallo-beta-lactamases (MBL) (Vardanyan and 
Hruby, 2016).  
1.4.1.4 Carbapenems 
Members of this group (e.g. imipenem, meropenem, ertapenem and 
doripenem) have the broadest spectrum of all ß-lactams against both Gram-positive 
and Gram-negative organisms. Importantly, non-fermenting bacteria (e.g. 
Acinetobacter and Pseudomonas spp.) have natural resistance against ertapenem. 
Many MDR Gram-negative strains are still sensitive to carbapenems and hence, today, 
they are the ultimate drugs used to treat various life threatining Gram-negative 
infections. (Bush and Karen, 2007; Papp-Wallace et al., 2011). That is why the fast 
emergence and spread of carbapenem resistance in Enterobacteriaceae (CRE) and that 
in K. pneumoniae (CRKP) is such a serious threat (CDC, 2018). 
1.4.2 Resistance to β-lactams antibiotics 
There are three main mechanisms by which bacteria can resist β-lactams: target 
modification, decreased intracellular concentration and by the production of beta-






1.4.2.1 Target alteration  
This is a common and highly effective mechanism in several Gram-positive 
bacteria (e.g. in methicillin resistant Staphylococcus aureus, MRSA or in 
Streptoccoccus pneumoniae), and is also present in some Gram-negative ones (e.g. the 
ß-lactamase negative, ampicillin resistant (BLNAR) strains of Haemophilus influenzae 
(Dever and Dermody, 1991; Lambert, 2005; Tristram et al., 2007).  However, in 
converting Enterobacteriaceae to ß-lactam resistant it has limited, if any role, hence it 
will not be further discussed here.  
1.4.2.2 Decreasing intracellular concentration 
The intracellular concentration of a drug can be limited by two ways: by 
expelling molecules already taken up or by limiting their uptake. The first mechanism 
is usually achieved by the up regulation of the expression of efflux pumps (Poole, 
2005; Webber and Piddock, 2003). These efflux pumps vary in their spectrum of 
compounds as they can expel from the cell, but often they are multi-drug efflux pumps 
(Aeschlimann, 2003; Rouveix, 2007; Sun et al., 2014). Although this spectrum may 
include various ß-lactam drugs in Enterobacteriaceae, in their cephalosporin and 
carbapenem resistance efflux pumps play a comparatively minor role, seldom leading 
to clinically significant level of resistance to these agents (Pages et al., 2009). 
The other mechanism is the modification of porins that form channels in the 
outer membrane or limiting their numbers with a consequent limited uptake of the 
drugs (Yang et al., 2010; Nikaido, 1989; Doumith et al., 2009). This mechanism has 
considerable effectiveness in Enterobacteriaceae in lowering the susceptibility to 






the restriction of uptake may not result in clinically significant reduction of 
susceptibility, once combined with the production of hydrolytic enzymes even with 
moderate activity against a particular extended spectrum beta-lactam, the combined 
effect of these two mechanisms can cause clinically significant cephalosporin or even 
carbapenem resistance. 
1.4.2.3 Enzymatic degradation of β-lactams 
Enzymatic inactivation of β-lactam agents is the most common and most 
effective resistance mechanism among Enterobacteriaceae against this group of 
antibiotics (Murray, 2013). 
There are two main classification schemes for ß-lactamases that are currently 
in use. The Ambler molecular system, based on conserved and distinguishing amino 
acid motifs, classifies β-lactamases into four molecular classes, i.e. A, B, C, and D, 
(Table 6).  On the other hand, grouping by the Bush-Jacoby-Medeiros system is based 
on the functional similarities (including substrate spectrum, EDTA and susceptibility 
to inhibitors, such as clavulanic acid, sulbactam and tazobactam) of the various 
enzymes forming four main, and multiple subgroups (Table 6) (Ambler, 1980; Bush 
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Class A contains beta-lactamases with a broadly varying substrate specificity 
from narrow spectrum penicillinases through extended-spectrum beta-lactamases 
(EBLS) hydrolyzing 3rd and 4th generation cephalosporins to carbapenemases. Several, 
but not all of them can characteristically be inhibited by β-lactamase inhibitors (see 
later). Their genes are often located on plasmids; therefor they have the ability to 
spread among members of the same species or even among different genera.  
The best-known representatives of this group are TEM and SHV type enzymes. 
The original molecules had relative narrow substrate spectrum. However, subsequent 
mutations have resulted into the considerable extension of the spectrum also including 
3rd and 4th generation cephalosporins (and in some case a low activity also against 
carbapenems) (Fong and Drlica, 2003; Harvey et al., 2007; Rupp and Fey, 2003). 
Currently, the CTX-M type of ESBLs, with characteristically high activity against 
cefotaxime, represent a rapidly growing family of molecular class A ESBLs. In recent 
years, the CTX-M type ESBLs became the most frequent ESBL type worldwide 
(Bonnet, 2004; Cantón et al., 2008; Eisner et al., 2006; Zowawi et al., 2013). 
Further members of this group are the enzymes with even broader activity 
spectrum, i.e. carbapenemases. An important example is the K. pneumoniae 
carbapenemases (KPC), first detected in USA in 1996, that is currently the most 
common carbapenemases at several parts of the World (Arnold et al., 2011; Nordmann 
et al., 2009; Sonnevend et al., 2015a; Won et al., 2011; Zowawi et al., 2014).  
Molecular class B enzymes are the so-called metallo ß-lactamases (MBL) that 
require a divalent cation for their activity and hence, can be inactivated by chelators, 
such as EDTA or dipicolinic acid (DPA). There are several broad-spectrum enzymes 






notable exception of monobactams. Similarly, to group A enzymes, their genes can 
often be found on mobile genetic elements. They are commonly present in non-
fermenting bacteria, such as Pseudomonas and Acinetobacter¸ but also spreading fast 
among Enterobacteriaceae. Examples of these enzymes are the VIM, IMP and the 
recently emerging New Delhi Metallo ß-lactamases (NDM) (Cornaglia et al., 2011; 
Ghazawi et al., 2012; Sonnevend et al., 2012; Walsh and Toleman, 2012). 
The most important types of class C enzymes are the AmpC-type enzymes. 
Some, if hyper-expressed, has broad spectrum activity which includes hydrolysis of 
3rd and 4th generation cephalosporins, and in some cases have even a moderate, weak 
activity against carbapenems. In some species the necessary high expression of the 
enzyme to achieve clinical resistance is inducible by ß-lactam drugs, while in others 
they are constitutively expressed (Hanson, 2003; Jacoby, 2009; Thomson, 2010). 
Molecular class D enzymes are primarily oxacillinases (OXA) that vary 
considerably in their spectrum. An important group even has carbapenemase activity, 
although some of these enzymes exhibit simultaneously no or moderate activity 
against cephalosporins (Evans and Amyes, 2014; Walther-Rasmussen and Høiby, 
2006). They predominantly occur in various non-fermenting Gram-negative rods, but 
currently a subset of them, the OXA-48-like enzymes, are fast spreading in 











1.4.3 Beta-lactamase inhibitors 
Beta-lactamase inhibitors (Figure 6) are the most powerful and clinically used 
antibiotic adjuvants to counteract resistance to beta-lactam antibiotics. The main role 
of these inhibitors is to protect the antibiotics from a very efficient bacterial 
inactivation mechanism involving beta-lactamases (González-Bello, 2017).   
Figure 6: Chemical structures of β-lactamase inhibitors (Docquier and Mangani, 
2018) 
 
The identification of inhibitors to common beta-lactamases started in the mid-
1970s, which was due to the appearance of the TEM-1 penicillinase in Neisseria 
gonorrhoeae (Ashford et al., 1976) and Haemophilus influenzae (Gunn et al., 1974; 
Khan et al., 1974). The first inhibitor discovered was clavulanic acid with a novel 
clavam structure with an inhibitor activity against staphylococcal penicillinases and 
most of the known plasmid-encoded penicillinases found in enteric bacteria (Reading 
and Cole 1977; Cole, 1982), including the widespread TEM and SHV enzymes 
(Simpson et al., 1980). Clavulanic acid is a so called “suicide inhibitor” as it is being 
inactivated while interfering with the enzyme to be inhibited (Charnas et al., 1978; 







Several, but not all, class A beta-lactamases, including ESBLs, can be inhibited 
by clavulanic acid (Steward et al., 2001) and that applies to some extent even to some 
of the class A carbapenemases (Nordmann and Poirel 2002; Yigit et al., 2003). Most 
extensively it is used in combination with amoxicillin considerably extending the 
spectrum of the drug particularly towards Gram-negative bacteria (Bush and Bradford, 
2016).   
After the discovery of clavulanic acid, chemists tried to synthesize a number 
of penicillanic acid sulfones with beta-lactamase inhibitory activity (English et al., 
1978; Fisher et al., 1981; Aronoff et al., 1984). Of these, sulbactam (English et al., 
1978) and tazobactam (Aronoff et al., 1984) were effectively commercialized. These 
two inhibitors had a similar range of activity as clavulanic acid. Sulbactam has 
somewhat less inhibitory activity against class A beta-lactamases compared to 
clavulanic acid or tazobactam but has an improved inhibition against class C 
cephalosporinase enzimes (Bush et al., 1993). The sulfone inhibitors do not work as 
inducers of chromosomally mediated AmpC Beta-lactamase (Weber and Sanders 
1990). Sulbactam has been combined with ampicillin (Neu, 1990) and in Japan it has 
been combined with cefoperazone to offer extra synergistic activity against non-
fermentative and anaerobic bacteria (Eliopoulos et al., 1989). On the other hand, 
tazobactam has been combined with piperacillin, cefoperazone and ceftolozane for 
nosocomial infections, including those caused by P. aeruginosa (Lister, 2000). 
Despite the structural similarities to “real” beta-lactam drugs, the inhibitors 
usually have limited antibacterial activity on their own with some exceptions. 
Clavulanic acid alone has an MIC as low as 1 mg/L against N.  gonorrhoeae (Wise et 






spp. and Burkholderia cepacea, respectively (Jacoby and Sutton 1989; Fass et al., 
1990; Dong et al. 2014). Importantly, none of these inhibitors inhibit the hydrolytic 
activity of MBLs (Bush, 2015), and that their activity against serine carbapenemases, 
if present at all, is not sufficient to convert enzyme producing isolates into clinical 
susceptibility (Yigit et al., 2003; Woodford et al., 2004; Moland et al., 2007). 
After a gap of almost two decades, a new class of non-beta-lactam beta-
lactamase inhibitors emerged based on a novel structure, i.e., diazabicyclooctane 
(DBO) (Coleman, 2011). The first inhibitor of this class is Avibactam which has a 
broader spectrum of activity than the previous inhibitors.  
The success of avibactam can be attributed first to the unique structural 
similarity to beta-lactams at the level of the electrophilic carbonyl group. This mimicry 
is significant for rapid formation of a stable adduct by beta-lactamases. The stable acyl 
enzyme formed by the carbamoyl link between the inhibitor and the enzyme active-
site serine residue considered the second significant attribute of this compound (Drawz 
et al., 2014).    
Avibactam can effectively inhibit not only class A penicillinases, ESBLs, and 
serine carbapenemases, but also class C cephalosporinases and some class D 
oxacillinases (Ehmann et al., 2012, 2013). It does not induce AmpC beta-lactamases 
at clinically applicable concentrations (Coleman, 2011). Avibactam, in combination 
with ceftazidime, has been approved in late 2014 by the FDA to treat complicated 
intra-abdominal and complicated urinary tract infections (González-Bello, 2017).  
Some other DBOs which are under development include RG6080 and 






spectrum of relebactam is similar to that of avibactam; however, except that it does 
not inhibit class D beta-lactamases, such as OXA-48 (Livermore et al., 2013). The 
other inhibitor RG6080 (earlier known as OP0565) is a DBO that has similar inhibitory 
spectrum to the other DBOs, but it has the extra benefit of showing some natural 
antibacterial activity against enteric bacteria (Livermore et al., 2015). The RPX7009 
(boronic acid) inhibitor is another new class of synthetic non-b-lactam b-lactamase 
inhibitors (Hecker et al., 2015). It has inhibitory activity against many groups of serine 
beta-lactamases (Hecker et al., 2015).  
None of these promising inhibitors has activity against class B enzymes. 
However, clinical trials using aztreonam in combination with ceftazidime are 
promising. MBLs do not hydrolyze aztreonam and the avibactam added may inhibit 
practically all, non MBL type beta-lactamases. (Drawz et al., 2014).  
1.4.4 Aminoglycosides 
The discovery of aminoglycosides through systematic screening of soil 
Actinobacteria started in the 1940s. Streptomycin was the first aminoglycoside to be 
discovered from Streptomyces griseus and since then, it has been successfully used for 
the treatment of tuberculosis and infections with Gram-negative bacteria (Doi et al., 
2016). The name “aminoglycoside” derives from the classic structure of these 
antibiotics having an amino-containing or non-amino-containing sugar residue 
connected to six-membered rings with amino group substituents. Subsequently, 
numerous aminoglycosides (Figure 7) have been identified or semi-synthesized and 
used in clinical practice. Based on their chemical structures, the aminoglycosides are 
grouped into 4,6-disubstituted 2-deoxystreptamine (DOS), 4,5-disubstituted DOS, and 







Figure 7: Structures of representative aminoglycosides (Krause et al., 2016) 
 
The first group includes gentamicin, tobramycin, and amikacin, which have 
been extensively used as intravenous or nebulized formulations in combination with a 
beta-lactam for the treatment of infections caused by Gram-negative bacteria, and 
atypical mycobacteria (also in combination with other active agents). The second 
group is represented by neomycin, which are limited in their use for being toxic and 
are given either orally or topically, but not intravenously. The monosubstituted DOS 
group is represented by apramycin, which is mainly used in veterinary medicine (Doi 
et al., 2016). Lately, a new semisynthetic version, plazomicin, was introduced to 
clinical practice, that is able to resist the most aminoglycoside destroying mechanisms 






Aminoglycosides lead to inhibition of polypeptide synthesis and to subsequent 
cell death by binding to the aminoacyl-tRNA recognition site (A-site) of the 16S rRNA 
which constitutes the 30S ribosomal subunit. They are the only protein synthesis 
inhibitor antibiotics with a bactericidal effect against most susceptible pathogens (Doi 
et al., 2016; Serio et al., 2018).  
1.4.4.1 Resistance to aminoglycosides 
There are several mechanisms by which bacteria can confer resistance to 
aminoglycosides of which: (1) enzymatic modification and inactivation of the 
aminoglycosides, mediated by aminoglycoside acetyltransferases, 
nucleotidyltransferases, or phosphotransferases (Ramirez and Tolmasky, 2010; Shaw 
et al., 1993); (2) increased efflux; (3) decreased permeability; and (4) modifications of 
the 30S ribosomal subunit; (5) target site modification which occurs through the action 
of 16S rRNA methyltransferases (RMTs). Mechanisms 1-4. have varying effects on 
different members of the class and frequently multiple mechanisms are involved in 
any given resistant isolate. Nevertheless, by choosing the right representative, often 
there is a chance to find a drug that is still clinically active. On the other hand, 
modification of the 16S ribosomal site usually affects most clinically relevant 
aminoglycosides (Krause et al., 2016; Takahashi and Igarashi., 2018) seriously 
restricting the use of these antibiotics. Hence, in the following paragraph, the focus 
will be on the 16S RMTs.  
RMTs consist of two main classes depending on the specific nucleotide 
residues that they modify. The first class includes enzymes that make the bacteria 
resistant to 4,6-di-substituted aminoglycosides via methylation of the N7 position of 






other class affects both 4,6- and 4,5-di-substituted aminoglycosides through 
methylation of the N1 position of nucleotide A1408 (Skeggs et al., 1985; Beauclerk 
and Cundliffe 1987; Mingeot-Leclercq et al., 1999).  
The first RMT described was armA in Klebsiella pneumoniae and rmtA in 
Pseudomonas aeruginosa (Galimand et al., 2003; Yokoyama et al., 2003). The armA 
gene was first reported in an isolate of K. pneumoniae from the urine of a patient in 
Paris in 2000 (Galimand et al., 2003; Gniadkowski et al., 1998).  armA was later 
confirmed to function as N7- G1405 16S-RMTase (Liou et al., 2006). rmtA was 
identified in a sputum isolate of P. aeruginosa in Japan in 1997 (Yokoyama et al., 
2003). Since then several others were described (Table 7) (Doi et al., 2016). 
Of the enzymes methylating at N1 A1408 position only a single representative 
has so far been described: npmA, was reported from an Escherichia coli clinical strain 
in Japan in 2007 (Wachino et al., 2007). It confers an even wider spectrum of 
aminoglycoside resistance than the N7 methylating ones including neomycin and 
apramycin (Dunkle et al., 2014). Importantly, several of these genes are located on 


































rmtA P. aeruginosa — Low Japan, Korea 
rmtB 





























rmtE E. coli CMY-2 AmpC Very low United States 















rmtH K. pneumoniae CTX-M ESBL Very low Iraq 
npmA 









Tigecycline is a glycylcycline antimicrobial agent that is structurally related to 
minocycline (Sun et al., 2013). Tigecycline can enter the bacterial cell by active 
transport or passive diffusion and, in the same way as tetracyclines, the antibiotic binds 
reversibly to the 30S ribosomal subunit, hindering the entry of tRNA into the A site of 






the bacterial growth (Noskin, 2005; Hirata et al., 2004; Hope et al., 2010; Khardori, 
2006). The addition of an N,N,-dimethylglycylamido group at the 9 position of the 
minocycline molecule increases the affinity of tigecycline for the ribosomal target up 
to 5 times when compared with minocycline or tetracycline (Nathwani, 2005).  
Tigecycline has a broad range of activity against many Gram-positive (such as 
MRSA and MRSE, penicillin-resistant Streptococcus pneumoniae, and VRE species), 
gram-negative (Citrobacter freundii, Escherichia coli, Enterobacter cloacae, 
Klebsiella species, Salmonella species, Serratia marcescens, and Shigella species) and 
anaerobic organisms (Zhanel et al., 2004; Nathwani, 2005; Fritsche and Jone, 2004).  
Activity of tigecycline and minocycline can also cover Acinetobacter species (Pachon-
Ibanez et al., 2004).  None of the tetracyclines have coverage against Pseudomonas 
aeruginosa. Tigecycline also does not have activity against certain Proteus strains, 
including Proteus mirabilis. A major disadvantage of tigecycline is its short half live 
in serum, so its main use is in soft tissue infections intrabdominal and lately, 
pneumonias (Stein and Babinchak, 2013; Wang et al., 2017).  
1.4.5.1 Resistance to tigecycline 
It has been reported that tigecycline is not affected by most of the common 
mechanisms of antibiotic resistance used by bacteria to avoid antibiotic therapy, due 
to the steric hindrance gained by the large D-ring substituent (Pankey, 2005). 
However, emergence of tigecycline resistance in K. pneumoniae isolates has been 
reported (Elgendy et al., 2018). Overexpression of rarA, a transcriptional activator of 
the oqxAB efflux pump, can induce a low level of resistance to tigecycline in K. 






Based on large-scale surveillance studies, tigecycline appears to hold low 
resistance rates of <10% among Enterobacteriaceae worldwide (Pournaras et al., 
2016). An overall non-susceptibility rate of <10% including ESBL-producing 
Enterobacteriaceae and CR K. pneumoniae, and <20% for MDR Enterobacteriaceae 
and CR Enterobacter spp. and S. marcescens was reported (Pournaras et al., 2016). 
On a worldwide basis, it has been found that E. coli exhibits lower non-susceptibility 
rates if compared to K. pneumoniae, E. aerogenes, E. cloacae and S. marcescens 
(Fern´andez et al., 2012). Using next-generation sequencing, Zheng et al identified 
several genes which probably encode efflux pumps or translational regulators in 
tigecycline-resistant K. pneumoniae, based on their sequence similarity to known RND 
efflux pump genes which can be related to tigecycline resistance (Zheng et al., 2014).  
It is clear that Tigecycline resistance mechanisms are complex in Enterobacteriaceae 
(Table 8) (Zheng et al., 2014; Wang et al., 2015; Pournaras et al., 2016). 
Table 8: Mechanisms implicated in tigecycline resistance among Enterobacteriaceae 
(Pournaras et al., 2016) 
Pathogen Suggested mechanism of tigecycline resistance 
Klebsiella pneumonia 
Overexpression of ramA and acrAB 
Deletions, insertions and point mutations in ramR 
Overexpression of rarA and oqxB 
IS5 element integration in a putative efflux pump, KpgABC 
Overexpression of marA and acrAB 
Structural alteration of the ribosomal protein S10 
Other RND efflux pump genes 
Enterobacter cloacae and Enterobacter 
aerogenes 
RamA- mediated mechanisms affecting AcrAB regulation 
Escherichia coli 
AcrAB and AcrEF RND efflux pumps 
Single nucleotide insertion in marR/ overexpression of MarA 
Proteus mirabilis AcrAB efflux pump 
Morganella morganii AcrAB efflux pump 
Serratia marcescens Upregulation of SdeXY–HasF efflux pump 
IS, insertion sequence; RND, resistance–nodulation–cell division. 
1.4.6 Fluoroquinolones 
The quinolones are a group of synthetic antimicrobial agents with major 






agents in the world. Initially, they were mostly used to treat Gram-negative infections, 
later they were modified in order to improve their pharmacokinetic properties and 
extend their antibacterial spectrum, to become effective against a wide variety of 
Gram-negative and Gram-positive pathogens (Correia et al., 2017).   
Nalidixic acid, as the first compound of the quinolones, was introduced into 
clinical use in 1962, for the treatment of uncomplicated urinary tract infections (UTIs) 
(Fàbrega et al., 2009; Bisacchi, 2015). The second generation of compounds, the 
fluoroquinolones, showed significantly improved activity and enhanced Gram-
positive penetration and better pharmacokinetic and pharmacodynamic properties 
(Aldred et al., 2014). The first representative of this generation was norfloxacin but 
ciprofloxacin, the most widely used representative, showed good activity also outside 
the urinary tract (Bisacchi, 2015).  Even after almost three decades in clinical use, the 
World Health Organization (WHO) listed ciprofloxacin as an essential, critically 
important antibiotic (Collignon et al., 2016). The huge success of ciprofloxacin led to 
the development of a newer generation of quinolones (levofloxacin, moxifloxacin, 
gatifloxacin, etc.) with broader and different spectrum of activity and pharmacokinetic 
properties (Aldred et al., 2014).  Fluoroquinolones have been used comprehensively 
for multiple clinical indications worldwide due to their power, wide activity spectrum, 
oral bioavailability and generally good safety profile (Hooper and Jacoby, 2016).  
The quinolones are known to target and inhibit the activity of two necessary 
bacterial type II topoisomerases: DNA gyrase and topoisomerase IV, respectively 
which play a vital role in the modulation of the chromosomal supercoiling required for 







The number of quinolone-resistant strains has been growing steadily, being 
observed in all species exposed to this antimicrobial class (Aldred et al., 2014; WHO, 
2014; Hooper and Jacoby, 2016). 
1.4.6.1 Resistance to fluoroquinolones 
Quinolone resistance can be due to several mechanisms (Figure 8). 
Chromosomally encoded mechanism are mutations modifying the target enzymes and 
their drug-binding affinity and those leading to reduced drug accumulation by either 
decreased uptake or increased efflux. Plasmid-coded resistance can be due to the 
production of proteins protecting the drug’s and to the expression of drug modifying 
enzymes (Aldred et al., 2014; Hooper and Jacoby, 2016; Kim and Hooper, 2014). 
These mechanisms often co-exist and act concomitantly leading to high levels of 
quinolone resistance (Hopkins et al., 2005; Hooper and Jacoby, 2016).  
 
       






Plasmid-mediated quinolone resistance (PMQR) is of particular importance 
due to the easy spread via conjugation. The first target-protecting mechanism was 
described in the late 1990s and have been broadly reviewed in the last decade (Jacoby 
et al., 2014; Rodríguez-Martínez et al., 2016; Ruiz et al., 2012). The first PMQR gene, 
qnrA, was reported in 1998 in a conjugative plasmid of a ciprofloxacin-resistant K. 
pneumoniae clinical isolate (Martínez-Martínez et al., 1998) and, nowadays, about 100 
Qnr variants have been identified, which has been classified into six distinct families: 
QnrA, QnrB, QnrS, QnrC, QnrD and QnrVC. It has been found that the Qnr proteins 
belong to the pentapeptide-repeat protein family and provide quinolone resistance by 
physically protecting DNA gyrase and topoisomerase IV from quinolone inhibition 
(Correia et al., 2017).  
The second mechanism for PMQR was discovered in 2006 as a bifunctional 
variant of an aminoglycoside-modifying acetyltransferase, AAC(6')- Ib-cr, that has 
two specific amino acid substitutions (Trp102Arg and Asp179Tyr). This variation 
made it able to acetylate the unsubstituted nitrogen of the C7 piperazine ring, which is 
present in quinolones such as ciprofloxacin, thus conferring quinolone resistance by 
decreasing the drug's activity. Soon after, a third mechanism for PMQR was found 
with the discovery of the plasmid- encoded efflux pumps QepA and OqxAB (Correia 
et al., 2017). 
In the presence of therapeutic levels of quinolones, PMQR provides a good 
background for selection of additional resistance mechanisms and hence for the 
emergence of high levels of quinolone resistance. It has been reported that PMQR 
genes found in transposons and/or integrons that are often co-located with other 






B-lactamase and carbapenemase genes) in MDR plasmids of significantly varying 
sizes and incompatibility groups. The circulation of multiple plasmids with such 
heterogeneity has been accountable for the wide geographic distribution of PMQR in 
a great variety of hosts (Correia et al., 2017). 
1.4.7 Polymyxins 
In an era of enormous and growing threat of increased bacterial resistance to 
almost all available antibiotics, drugs, such as the polymyxins, previously confined to 
topical use, only due to their toxicity are re-entering the therapeutic armory against 
Gram-negative bacteria (Yu et al., 2015; Poirel et al., 2017). Consequently, 
polymyxins are often considered as the last option of antibiotic therapy for MDR 
bacteria (Rice, 2006; Li and Nation, 2006).  
The polymyxins consist of polymyxins A till E, of which only polymyxin B 
and polymyxin E (colistin) are now used clinically. In general, both have a narrow 
antibacterial spectrum restricted to Gram-negative bacteria (Li et al., 2007). Most 
members of the Enterobacteriaceae family, including Escherichia coli, Enterobacter 
spp., Klebsiella spp., Citrobacter spp., Salmonella spp., and Shigella spp.) and the 
common non-fermenters (Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Stenotrophomonas maltophilia) are naturally susceptible (Falagas and Kasiakou, 
2005). Some species are naturally resistant to polymyxins, including Proteus spp., 
Morganella morganii, Providencia spp., Serratia marcescens.  Polymyxins are not 
active against Gram-negative cocci (Neisseria spp.), Gram-positive bacteria, and 
anaerobic bacteria (Falagas and Kasiakou, 2005). 






soil bacterium Paenibacillus polymyxa subsp. colistinus (Benedict and Langlykke, 
1947; Biswas et al., 2012).  In the 1980s, the parenteral use of polymyxin was almost 
completely abandoned due to the emergence of less-toxic aminoglycosides and other 
antipseudomonal agents (Poudyal, et al., 2008). 
Polymyxins are cationic polypeptides that contains a cyclic heptapeptide 
possessing a tripeptide side chain acylated at the N terminus by a fatty acid tail (Falagas 
et al., 2010; Li et al., 2006) (Figure 9).  
 
 
Figure 9: Structures of colistin A and B, colistimethate A and B, and polymyxin B1 







The intrinsic toxicity of colistin may be due to the hydrophobic properties of 
the N-terminal fatty acyl segment, which also play a significant role for its 
antimicrobial activity, and also by positions 6 and 7, which are very important (Brink 
et al., 2014; Gallardo-Godoy et al., 2016). Colistin and polymyxin B are different by 
just a single amino acid in the peptide ring (Figure 9) (Nation et al., 2014). While the 
polymyxin B is administered directly as an active antibiotic, the colistin must be 
administered as an inactive prodrug, colistin methanesulfonate (colistimethate [CMS]) 
(Nation et al., 2014).  
The cationic polymyxins bind to the anionic outer membrane of Gram-negative 
bacteria and destabilize the lipopolysaccharide (LPS) increasing the permeability of 
the bacterial membrane, leading to outflow of the cytoplasmic content and eventually 
cell death (Li et al., 2006; Falagas and Kasiakou, 2005). They may also have a direct 
destabilizing effect in the inner membrane (Li et al., 2005) and also inhibit vital, 
membrane bound respiratory enzymes (inhibition of type II NADH-quinone 
oxidoreductases [NDH-2]) (Deris et al., 2013). 
1.4.7.1 Resistance to polymyxins 
The most common way of acquiring resistance to polymyxins is the alteration 
of the LPS via cationic substitution that prevents the binding of the cationic drug 
(Poirel et al., 2017; Velkov et al., 2010). This can be achieved by mutations in several 
chromosomal genes that are part of the complex system responsible for the synthesis 
of LPS (Fern´andez et al., 2013; Loutet et al., 2011). The most common polymyxin 
resistance mechanism in bacteria is due to the shielding of phosphates on lipid A with 
positively charged groups, such as phosphoethanolamine (pEtN) and L-4-






complex pathways are regulated at multiple levels including the PhoP-PhoQ 








Figure 10: Regulation pathways of LPS modifications in Klebsiella pneumoniae 
(Poirel et al., 2017) 
 
Recently, a plasmid-mediated colistin resistance gene, mcr (mobile colistin 
resistance) was discovered first for E. coli and K. pneumoniae isolates recovered in 
China between 2011 and 2014 (Liu et al., 2016).  The overall, production of MCR-1 
in E. coli leads to an increase of the MICs of polymyxins. As a result, without any 
additional resistance mechanisms, the expression of MCR-1 is enough to confer 
resistance to colistin in E. coli and other enterobacterial species (Poirel et al., 2017). 










1.5 Aims and objectives 
Long Term Aims 
o To obtain the very first insight into the distribution of various types of 
Klebsiella pneumoniae causing blood-stream infections in the UAE 
 
Specific Objectives  
o To establish the antimicrobial susceptibility of K. pneumoniae causing 
bloodstream infections 
o To assess the rate of and characterize Carbapenem Resistant K. pneumoniae 
(CRKP) 
o To study the rate of hypervirulent strains among bloodstream causing K. 
pneumoniae (hvKP) 
o To characterise these strains regarding their clonal types and virulence markers 











Chapter 2: Material and Methods 
2.1 Bacterial strains 
A total of 125 non-repeat K. pneumoniae bloodstream isolates were collected 
in a two-year period, from January 2014 to December 2015, in Tawam Hospital 
(Microbiology Department), a tertiary care hospital in Al Ain City, United Arab 
Emirates (UAE).  Duplicate isolates from the same patient were excluded and only the 
first isolate from each case was included.  Initially, the strains were speciated using the 
standard microbiological procedure, i.e. VITEK® 2 ID-GN (BioMérieux, France).  
Isolates were stored in duplicates in Tryptic Soy Broth (TSB, Mast) containing 10% 
glycerol (Univar) at -80°C freezers. Prior each experiment strains were revived on 
Tryptic Soy Agar (TSA, Mast) and incubated for 24 h at 37°C.   
2.2 Antibiotic susceptibility testing 
For each pure isolate, the antimicrobial sensitivity testing was performed by 
disc diffusion technique as described in the guidelines of the Clinical and Laboratory 
Standard Institute (CLSI, 2015).  All stored K. pneumoniae isolates were freshly 
cultured on Tryptic-soy agar (TSA) plates. From the cultures, 0.5 McFarland density 
suspension was made in in sterile 1xPBS and this was spread onto ready-made 
Mueller-Hinton agar (MHA) plates (Pangulf Lab Solution) using a sterile cotton 
applicator swab (Citoswab, China) to provide semi-confluent growth. Antibiotic disks 
(MAST) were applied using antibiotic dispenser (MAST), seven discs per a 90 mm 
dish. All plates were incubated at 37°C for 18 h.  Diameters of the zone of inhibition 
were measured with a caliper. The following antibiotics were used: Amikacin (AK), 
Ampicillin (AP), Amoxicillin-clavulanic acid (AUG), Aztreonam  (AZT), Ceftazidime 
(CAZ), Chloramphenicol (CHL), Ciprofloxacin (CIP), Cefpodoxime (CPD), 






Cefoxitin (FOX), Gentamicin (GN), Imipenem (IMP), Meropenem (MEM), Nalidixic 
acid (NA), Piperacillin-tazobactam (PTZ), Trimethoprim-sulphamethoxazole (SXT), 
Tetracycline (T) and Tobramycin (TOB). 
For quantitative assay the broth microdilution assay was used.  The quantitative 
susceptibility test was established against colistin (COL) only. Colistin was serially 
diluted in 100 µl volume of Muller Hinton Broth (OXOID) in 96 well microplates 
(Sarstedt, Germany) and inoculated by a Multipoint inoculator (MAST) to give a final 
concentration of 5 x 105 colony forming units (CFU)/ml.  After 18 hours of incubation 
at 37°C the growth was visually assessed and the Minimum Inhibitory Concentration 
of the drug (MIC) was determined as the lowest concentration preventing visible 
growth of the organism tested.    
Escherichia coli ATCC 25922 was used as control strain in all susceptibility 
testing, and E. coli ABC149, an mcr-1 positive isolate with colistin MIC of 4mg/L was 
additionally used in the colistin susceptibility testing. 
Strains were considered to be multi-drug resistant if resistant to three or more 
classes of drugs (Magiorakos et al., 2012). 
2.3 Strategy for screening for, and characterization of hypervirulent Klebsiella 
pneumoniae 
 All strains were screened by PCR for the presence of the iucA (Russo et al., 
2014) and rmpA (Brisse et al., 2009) genes. Those positive for iucA were also tested 
for rmpA2 (Yu et al., 2015). A strain was considered to be hypervirulent if positive for 
iucA and for rmpA and/or rmpA2. The capsule type (Brisse et al. 2009, Turton et al., 
2010) and the MLST (Diancourt et al., 2005) of the hvKP strains was also determined. 






various siderophore genes, namely kfuBC (Brisse et al., 2009), enterobactin (entB), 
salmochelin (iroB), Yersiniabactin (irp2) and aerobacting (iucA) (Russo et al., 2014) 
and their positivity in string test (Patel et al., 2014; Martin and Bachman, 2018). 
2.4 Extraction of bacterial genomic DNA for PCR 
Three to five colonies of isolates grown overnight on TSA plates were picked 
by toothpick and suspended into two 200 μl aliquots of sterile distilled water in 
Eppendorf tubes.  The tubes were incubated for 10 minutes at 99°C on a thermo-block 
(Eppendorf).  They were centrifuged for 10 minutes at 14,800 rpm; the supernatant 
was collected without touching the pellet, combined in a new autoclaved Eppendorf 
tube and kept at 4°C.  This material was used for most experiments as the DNA target.  
For selected isolates, DNA was extracted using the QIAamp DNA Mini Kit (Qiagen) 
according to the manufacturers’ instruction. 
2.5 Polymerase Chain Reaction (PCR) 
All PCR reactions were performed on Applied Biosystems 2700 and 2720 
thermocyclers.  In all reactions E. coli J53RAZ genomic DNA and ultra-pure distilled 
water were used as negative controls. All positive reactions first obtained were 
confirmed by direct sequencing.  The genes targeted, the primers and parameters used 
in different PCR reactions with respective references are listed in Table 9.  PCR 
reactions were performed for 30-40 cycles at various annealing temperatures 
depending upon the melting temperature of the primer set used.  Amplicons were 
analyzed on 1-2% agarose gels in the presence of ethidium bromide.  Gels were 
photographed and scanned using the Biometra gel documentation system (Biometra, 
Gottingen, Germany). To assess the molecular mass of the amplicons Gene Ruler 100 









Table 9: Primers used in the study 
Gene Targeted Primers 
Sequences 
(5’- 3’) 









SCS ATG TGC AGY ACC AGT AA 
CCG CRA TAT GRT TGG TGG TG 
543bp 
 
5’ at 94°C 
 
30X (30” at 94°C, 
30” at 55°C and 60” 
at 72°C) 
10’at 72°C 







438bp 5’ at 94°C 
 
40X (30”at 94°C, 40” 









798bp 5’ at 94°C 
 
40X (30”at 94°C, 40” 













40X (30”at 94°C, 40” 












5’ at 94°C 
 
40X (30”at 94°C, 40” 














30X (30”at 94°C, 30” 
at 60°C, 60” at 72°C) 
 


















Table 9: Primers used in the study (continued) 
Gene Targeted Primers 
Sequences 
(5’- 3’) 












5’at 94°C  
40 X (15” at 94°C, 












































35 X (30” at 94°C, 





































Table 9: Primers used in the study (continued) 
Gene Targeted Primers 
Sequences 
(5’- 3’) 









GGC GAA ATG GCW GAG AAC CA 
GAG TCT TCG AAG TTG TAA CC 
501 bp 5’at 94°C 
 
35X (60” at 94°C, 











TGA AAT ATG ACT CCA CTC ACG G 
CTT CAG AAG CGG CTT TGA TGG CTT 
450 bp 5’at 94°C 
 
35X (60” at 94°C, 







CCC AAC TCG CTT CAG GTT CAG 
CCG TTT TTC CCC AGC AGC AG 
477 bp 
5’at 94°C 
35X (60” at 94°C, 






GAG AAA AAC CTG CCT GTA CTG CTG 
GC 





ACC TAC CGC AAC ACC GAC TTC TTC 
GG 





CTC GCT GCT GGA CTA TAT TCG 





CTT TAT ACC TCG GTA CAT CAG GTT 
ATT CGC CGG CTG RGC RGA GAG 
414 bp 5’at 94°C 
 
35X (60” at 94°C, 



















Table 9: Primers used in the study (continued) 
Gene Targeted Primers 
Sequences 
(5’- 3’) 









GGT GCT CTT TAC ATC ATT GC 
GCA ATG GCC ATT TGC GTT AG 
1280 bp 
5’at 94°C  
35X (30” at 94°C, 










ACT GGG CTA CCT CTG CTT CA 






GAA GTG ACG CTG TTT CTG GC 
TTT CGT GTG GCC AGT GAC TC 
797 bp 







35X (30” at 94°C, 




























35X (30” at 94°C, 






























Table 9: Primers used in the study (continued)  
Gene Targeted Primers 
Sequences 
(5’- 3’) 














35X (30” at 94°C, 



























340 bp 5’at 94°C 
 
35X (30” at 94°C, 









609 bp 5’at 94°C 
35X (30” at 94°C, 
30” at 55°C and 60” 
at 72°C) 
10’at 72°C 








2.6 String test 
The string test was conducted to check the hypermucoviscosity of Klebsiella 
pneumoniae colonies.  The outcome result was defined as positive when an inoculation 
loop was able to generate a viscous string test of  ≥5 mm in length from a colony on a 
blood agar plate after overnight incubation (Patel et al., 2014; Martin and Bachman, 
2018), meanwhile, a negative string test was assigned when the string was less than 5 
mm in length or no string was formed at all.   
2.7 Pulsed Field Gel Electrophoresis (PFGE) 
PFGE was performed according to Gautom.  Briefly, bacterial strains grown 
on TSA plates were suspended in 2ml of cell suspension buffer (100 mM Tris, 100 
mM EDTA, pH8.0) up to a density of 3 McFarland unit and suspensions were kept on 
ice. Simultaneously, 1% plug (low melting point) agarose (Sigma) was melted in 1% 
SDS in TE buffer (10mM Tris:1mM EDTA pH8.0) and kept at 54°C. 500 μl bacterial 
suspensions, 25 μl of proteinase K (Invitrogen) (20 mg/ml) and 525 μl of 1% plug 
agarose were combined, mixed carefully, quickly transferred into 1 ml syringes and 
kept for 15-30 minutes at room temperature to allow the solidification of the agarose. 
Aliquots of 5 ml cell lysis buffer (50 mM Tris: 50 mM EDTA pH 8.0, 1% Sarkosyl) 
and 25 μl proteinase K 20 mg/mL were distributed into 50 ml tubes and 1mm thick 
slices of agarose plugs were directly cut into them.  They were incubated for 2 hours 
at 50°C in a shaking water bath (200 rpm).  Subsequently, the plugs were washed twice 
with 10 ml of preheated sterile MilliQ water for 20 minutes in a 50°C shaker water 
bath.  Plugs were washed four times each for 20 minutes with 10 ml of preheated TE 






Genomic DNA within the plugs were digested overnight at 37°C in a 100 μl 
restriction mixture made of 10 μl of NE buffer 4 (New England Biolabs), 1 μl of BSA 
(New England Biolabs), 30 U (1.5 μl) of XbaI enzyme (New England Biolabs) and 
87.5 μl of sterile distilled water.  Following digestion, the restriction mixtures were 
removed, and the plugs were incubated in 250 μl of 0.5X TBE buffer for 30 minutes 
at room temperature.  Subsequently, plugs were inserted into wells of 1.4% of agarose 
gel (Pulse Field Running Agarose A2929, Sigma) prepared in 0.5xTBE buffer each 
gel contained Salmonella Braenderup strain H9812 as references standard for PFGE 
loaded on three wells: two sides and a middle one.  Gels were run in CHEF Mapper 
(Biorad) electrophoresis chamber in 0.5X TBE buffer pre-chilled to 14°C. The running 
program consisted of 26 hours run at 6 V/cm with 120 angle and an initial switch time 
of 2.2 seconds and a final switch time of 54.2 seconds with linear ramp.  
Gels were stained with ethidium bromide for 20 minutes, followed by de-
staining in MilliQ water. Bands were detected and photographed under UV light in a 
Biometra gel documentation system. Gel pictures were stored as .tif files for further 
analysis. The GelCompare II software (Applied Maths, Sint-Martens-Latem, Belgium) 
was used to analyze the banding patterns. The Unweighted Pair Group Method with 
Arithmetic Mean (UPGMA) tree graphically showing the level of relatedness between 
the isolates was created based on the Dice similarity coefficient (SD) (with a 1.5% 
position tolerance). For a routine analysis, strains showing patterns with SD ≥ 80% 







2.8 Multi-locus Sequence Typing (MLST)  
In order to study the relatedness of K. pneumoniae strains, their genomic DNA 
were typed by MLST method based on the protocol described by (Diancourt et al., 
2005) The seven housekeeping genes of seven K. pneumoniae (ropB, gapA, mdh, pgi, 
phoE, infB, tonB) were amplified by the primers shown in Table 9 K. pneumoniae 
isolates were assigned to sequence types using the tools onto the following webpage 
(https://bigsdb.pasteur.fr/klebsiella/klebsiella.html). All hvKP strains were subjected 
to MLST. For carbapenem resistant K. pneumoniae strains, if isolates formed a PFGE 
cluster with >4 members, selected members of the cluster were investigated by MLST. 
For this purpose, PFGE subtypes were assigned to each isolate exhibiting >90% PFGE 
pattern similarity, and at least one isolate from each subtype was MLSTed. 
2.9 Sequencing 
PCR products were purified by PCR purification kit (Promega) prior to 
sequencing. Sequencing was done using the Big Dye Cycle Terminator V.3.1 (Applied 
Biosystems) according to the manufacturer's instructions. The samples were 
sequenced in both directions using the 3130X Genetic Analyzer (Applied Biosystems). 
Sequences were analyzed using the MEGA5 
(http://www.megasoftware.net/mega5/mega.html) and the Clone Manager v9 (Sci-Ed 
software) software. 
2.10 Plasmid electrophoresis and localization of the rmpA gene by hybridization 
Plasmids were isolated of the rmpA positive isolates by the alkaline lysis 
method of Kado and Liu (1981). Briefly, bacterial cells were collected from overnight 
culture on TSA plates, and suspended in 250µl of lysing solution (3%SDS, 50 µM 






45 minutes, with gentle mixing every 15 minutes, followed by addition of 250 µl of 
phenol-chloroform (1:1) and centrifugation at 13000 rpm for 15 minutes. About 100 
µl of the top aqueous layer was transferred to another tube containing 5 µl loading dye. 
Thirty µl of these samples were loaded in 0.8% agarose gel and subjected to 
electrophoresis at 130 V for 4 hours. Gels were stained with ethidium bromide for 20 
minutes followed by, de-staining with distilled water for 10 minutes. Rulers were 
placed around the gel, then photographed to help locate the bands using a gel 
documentation system (Biometra, Germany). For plasmid size control, E. coli  39R861 
(Threlfall, Rowe, Ferguson, & Ward, 1986) were used. The gel was then depurinated 
in 0.25 M HCl, then denatured in 0.5 M NaOH, 1 M NaCl, and lastly neutralized in 1 
M Tris, 0.6 M NaCl. All steps were repeated twice for 15 minutes, with gentle 
agitation, at room temperature; with the gels being rinsed with distilled water between 
the steps.  
The gel was transferred to Hybond N+ nylon membrane using capillary action; 
with overnight soaking in 20XSSC (saline-sodium citrate). The following day, 
membranes were cross-linked using UV at 70 000 microjoules. Hybridization was 
done using the DIG DNA detection kit (Roche, Germany). rmpA probe previously 
labelled with the same kit was used. The nylon membrane was incubated in 
hybridization buffer, at hybridization temperatures for 30 minutes as a 
prehybridization step, after which the hybridization buffer containing the probe was 
added, incubated overnight at the hybridization temperature. Hybridization 
temperature was calculated based on the size and the GC ratio of the probe using the 
formula given by the manufacturer. On the next day, membranes were washed twice 
with 2XSSC/1%SDS for 5 minutes at room temperature, followed by washing twice 






buffer at room temperature incubated in blocking solution for 30 minutes, followed by 
incubation in antibody solution for 30 minutes. After that, membranes were washed 
twice in washing buffer, and equilibrated in detection buffer. Finally, membranes were 
incubated in color substrate solution, kept in the dark without shaking till the 
appearance of the labelled band.  
2.11 Collection of clinical data 
Data on the age, gender, nationality, underlying illness, prior antibiotic 
exposure of the patients were provided by Dr. Rayhan Hashmey (Tawam Hospital).  
2.12 Ethical approval 
The study was approved by the Al Ain Medical District Human Research 
Ethics Committee (AAMD/HREC) No. 14/03 – CRD 309/14. 
2.13 Statistical analysis 
Categorical variables were compared by two-tailed Fisher’s test while the 
unpaired, two-tailed Student’s t test was used to compare means. P value of <0.05 was 











Chapter 3: Results 
 
3.1 General characteristics of the group of patients 
In total, 125 K. pneumoniae strains, the first such isolates were recovered from 
blood samples of individual patients and were included in the study. Information on 
gender, age, nationality and limited clinical data were available only for 122 patients. 
The average age all patients included in the study was 45.58 ± 30.64 years and 
representing ages 61 male and 61 female patients with respective average ages of 47.66 
± 32.18 and 43.49 ± 29.13 years. The distribution of the strains by the patients’ 
nationality is shown wards, by nationality of the patients are show in Table 10. 
 
Table 10: Distribution of isolates by the patients’ nationalities 
 
 
As co-morbidities can considerably impact the type of infection acquired, the  
frequencies of selected co-morbidities, specifically diabetes mellitus, haematological  
malignancies and solid tumours among patients are shown in Table 11. 
 
Nationality % Nationality % 
Afghani 1.6 Palestinian 4.8 
Bangladeshi 0.8 Saudi 0.8 
Comoros Islandic 0.8 Serbian 0.8 
Djiboutian 0.8 Sudanese 6.4 
Egyptian 2.4 Syrian 2.4 
Emirati 55.2 Yemeni 2.4 
Ethiopian 0.8 No data 2.4 
Philippine 1.6 Jordanian 2.4 
Indian 3.2 Omani 1.6 












Previous exposure to antibiotics may select organisms with high resistance 
profiles. Therefore, data were also collected on exposure to antibiotics within the 
previous one months. The data are summarised in Table 12. 









Diabetes mellitus 27.2 
Malignancy 41.6 
   Haematological 10.4 
   Solid tumour 31.2 
Diabetes and malignancy 14.4 
None of the above 43.2 
No data 2.4 
Antibiotic exposure % 
Any antibiotics 52.8 
None 44.8 
Any non-beta-lactams, only 2.4 
Any beta-lactams 50.4 
3rd gen. cephalosporins 5.6 
Carbapenems 14.4 

















3.2 Heterogeneity of the strains 
First, the level of heterogeneity of the K. pneumoniae strains was established 
by macro-restriction analysis via PFGE (Figure 11).   
The population was rather heterogenous forming 36 distinct clusters and 18 
singletons. The size of clusters is shown in Table 13. 
 








The analysis done if larger groups of strains also clustered in time and location.  













7 members 1 
9 members 1 






Table 14: Distribution of larger clusters in time and space 
 
PFGE cluster Date of isolation Ward 
PF12 
31-01-2014 Surgical Unit 2 
10-02-2014 Pediatric Intensive Care 
11-03-2015 Medical Unit 3 
27-04-2015 Pediatric Intensive Care 
PF42 
21-02-2014 Intensive Care Unit 
22-10-2014 Special Medical Unit 
01-11-2014 Intensive Care Unit 
29-11-2015 Oncology Unit 1 
PF51 
05-03-2014 Hematology Unit 2 
19-08-2014 Intensive Care Unit 
21-08-2014 Intensive Care Unit 
31-08-2015 Intensive Care Unit 
PF27 
21-03-2014 Pediatric Intensive Care 
21-03-2014 Intensive Care Unit 
08-04-2014 Intensive Care Unit 
29-09-2014 Emergency Department 
13-02-2015 Intensive Care Unit 
04-07-2015 Medical Oncology 
26-05-2015 Surgical Unit 1 
PF28 
24-01-2014 Surgical Unit 1 
02-02-2014 High Dependency Unit 
24-04-2014 Intensive Care Unit 






Table 14: Distribution of larger clusters in time and space (continued) 
  *   Strains marked are iucA positive, but were rmpA/A2 negative isolates, see later 
 
While limited clustering in time and space (e.g. PF32 in the Intensive Care Unit 
within a few weeks-times in 2014) did occur, no single locus explosive outbreak was 
indicated by the analysis.  
This observation was further supported by performing MLST of selected 
members of PFGE clusters with >4 member. The sequence type (ST) of isolates 
PFGE cluster Date of isolation Ward 
 10-01-2015 Hematology Unit 2 
22-01-2015 Intensive Care Unit 
22-04-2015 Intensive Care Unit 
26-05-2015 Surgical Unit 1 
22-10-2015 Pediatric Intensive Care 
PF32 
18-08-2014* Intensive Care Unit 
04-09-2014* Intensive Care Unit 
16-09-2014* Intensive Care Unit 
18-11-2014* Intensive Care Unit 
29-03-2015* Oncology Unit 1 
21-05-2015* Medical Unit 3 
08-06-2015* Oncology Unit 1 
15-08-2015 Special Medical Unit 3 
02-09-2015* Intensive Care Unit 
16-11-2015* Special Medical Unit 3 






exhibiting <90% PFGE pattern similarity is shown in Table 15. MLST also confirmed 
the heterogeneity of isolates, as members of the PF27 cluster belonged to three STs, 
PF28 cluster had isolates of seven various STs, and even the most uniform PF32 group 










Table 15: Subtypes and multi-locus sequence types of isolates belonging to PF clusters with >4 members 
UAEU No. 




based on >90% 
similarity 




PF27a NT NT NT NT NT NT NT NT 
BC-14-112 PF27a ST29 2 3 2 2 6 4 4 
BC-14-288 PF27b ST29 2 3 2 2 6 4 4 
BC-15-22 PF27c NT NT NT NT NT NT NT NT 
BC-14-96 PF27c ST714 2 3 2 2 6 4 160 
BC-14-95 PF27c ST714 2 3 2 2 6 4 160 




PF28a ST3550 2 1 1 224 9 4 12 
BC-14-47 PF28b ST1770 18 22 18 63 11 13 179 
BC-15-13 PF28c ST23 2 1 1 1 9 4 12 
BC-15-106 PF28d ST334 18 22 18 22 25 37 51 
BC-14-314 PF28e ST35 2 1 2 1 10 1 19 
BC-14-130 PF28f ST23 2 1 1 1 9 4 12 
BC-15-55 PF28f ST3549 2 1 1 1 9 191 12 
BC-15-61 PF28g ST2433 2 106 4 158 248 1 19 
BC-14-31 PF28h ST23 2 1 1 1 9 4 12 
BC-14-280 
PF32 
PF32a ST231 2 6 1 3 26 1 77 
BC-15-54 PF32a ST231 2 6 1 3 26 1 77 
BC-15-43 PF32a ST231 2 6 1 3 26 1 77 
BC-14-272 PF32a NT NT NT NT NT NT NT NT 
BC-15-117 PF32a NT NT NT NT NT NT NT NT 
BC-15-60 PF32a NT NT NT NT NT NT NT NT 
BC-14-237 PF32a NT NT NT NT NT NT NT NT 
BC-15-89 PF32a NT NT NT NT NT NT NT NT 
BC-15-125 PF32a NT NT NT NT NT NT NT NT 
BC-14-355 PF32b ST231 2 6 1 3 26 1 77 






3.3 Antibiotic resistance of the isolates 
 The susceptibility rates to specific antibiotics are shown in Table 16. 














Based on these figures, 47 isolates (37.6%) were multi-drug resistant, i.e. 
resistant to three or more classes of antibiotics (Magiorakos et al., 2012). Those 
patients who received antibiotic therapy prior to the isolation of K. pneumoniae from 
the blood sample were significantly more likely to harbour an MDR isolate 




























infection (Table 16). 
Furthermore, 15 isolates (12.0%) qualified as carbapenem resistant K. 
pneumoniae (CRKP), i.e. exhibiting non-susceptibility to at least one (always 
including ertapenem) of the carbapenems tested. Patients from whom CRKP were 
isolated were not exposed to antibiotics or to beta-lactam antibiotics more often than 
other patients (P=0.0503 and 0.0986). However, they were highly significantly more 
likely to receive prior carbapenem therapy (P=0.0098). No correlation between being 
infected with a CRKP strain and the presence of diabetes mellitus or any malignancy 
or being Emirati or non-Emirati was found either (P=1.0, 0.4059, 0.7887, respectively) 
(Table 17). 
Table 17: Correlation of different variables with having a multi-drug, or carbapenem 
resistant K. pneumoniae (CRKP) infection 
# n is the number of patients whose data were available 
MDR: Multi-drug resistant, CRKP: Carbapenem resistant K. pneumoniae, CSKP: carbapenem 
susceptible K. pneumoniae 
Variables MDR (n=44)# Non MDR (n=78) P 
Prior antibiotic therapy 31 35 0.0081 
Malignancy 21 31 0.4478 
Diabetes mellitus 11 26 0.4138 







Prior antibiotic therapy 12 54 0.0503 
Prior beta-lactam therapy 11 52 0.0986 
Prior carbapenem therapy 6 12 0.0098 
Malignancy 8 43 0.4059 
Diabetes mellitus 4 30 1.0 






3.4 Susceptibility of the carbapenem resistant isolates to non-beta-lactam 
antibiotics 
 Although the most common mechanisms causing resistance to carbapenems in 
Enterobacteriaceae does not cause resistance to non-beta-lactams antibiotics, per se, 
often carbapenem resistant strains exhibit non-susceptibility to several drugs of 
different classes. The comparison is done for the susceptibilities of strains to such 
antibiotics. As can be seen on Table 18, with the exception of fosfomycin and colistin, 
CRKP strains were significantly less often susceptible than their carbapenem 
susceptible, CSKP, counterparts. 
Table 18: Comparative susceptibilities of carbapenem resistant (CRKP) and 




% Susceptible Significance 
(P) CRKP CSKP 
Amikacin 6.7 98.2 < 0.0001 
Gentamicin 13.3 86.4 < 0.0001 
Tobramycin 0.0 82.7 < 0.0001 
Ciprofloxacin 6.7 87.3 < 0.0001 
Trimethoprim–
sulfamethoxazole 
6.7 73.6 < 0.0001 
Doxycycline 53.3 79.1 0.0482 
Chloramphenicol 6.7 87.3 < 0.0001 
Fosfomycin 100.0 100.0 1.0 






3.5 Molecular characterization of carbapenem resistant Klebsiella pneumoniae 
 The mechanism of carbapenem resistance was determined by subjecting the 
isolates to PCR targeting the most common carbapenemase enzymes. The results are 
shown in Table 19. All strains produced at least one carbapenemase, with the exception 
of one that expressed both NDM and an OXA-48-like genes. 
 






Eleven (73.3%) of the CRKP strains carried a blaCTX-M gene, while the same 
figure among the CSKP isolates was 20.1% (P=0.0001). 
As with the exception of two CRKP strains, all isolates exhibited non-
susceptibility to all the aminoglycosides tested. Exploring the presence of 16S 
methylase genes and with exception of the above mentioned two isolates, all CRKP 
strains carried such genes. Actually, 10 (69.1%) carried rmtF, while 3 (20%) carried 
armA. In none of the CSKP isolates could detect any 16S methylase genes, irrespective 
of the spectrum of their aminoglycoside resistance. 
No mobile colistin resistance genes were detected in any of the colistin resistant 
strains. 











The macrorestriction analysis of the CRKP strains revealed that beyond 5 
singletons, 10 of them belonged to a single cluster, PF32. The MLST analysis revealed 
that two singletons belonged to ST14, further 3 belonged to ST23, ST307 and ST70, 
respectively. The 10 member-strong cluster was made up by ST231 isolates, all 
expressing the blaOXA-232, rmtF genotype. 
3.6 Screening for hypervirulent strains 
 All strains were screened for the presence of rmpA and iucA genes and those 
carrying iucA were also tested for rmpA2. Strains carrying iucA and rmpA and/or 
rmpA2 were considered hypervirulent. Of the 125 strains tested, only 13 (10.4%) 
fulfilled the criteria. 
3.7 Characterization of hypervirulent strains 
3.7.1 Molecular typing of hypervirulent strains 
 In order to assess more subtle relationships between hvKP strains their PFGE 
patterns were reanalysed without the effect of the large number of cKP outliers. As 
seen in Figure 12, 6 strains formed a large cluster (previously assigned to PFGE 
patterns PF28 in Figure 11) while two strains (previously belonging to PF27) formed 









Figure 12: Macro-restriction patterns of the hvKP strains-dashed line indicates 80% 
similarity 
 
MLST analysis of the strains revealed that the 6 isolates clustering together all 
belonged to ST23 or CC23, i.e. single locus variants (SLV) of ST23, while the duplets 
were ST714 (Table 20).  
Table 20: Sequence types, date and location of isolation of hvKP strains 
 
 
As can be seen in Table 20, strains were not recovered from an explosive 
outbreak, but the distribution of isolation times and location are rather heterogenous. 
Strains Sequence type Date of isolation Ward 
BC-15-61 ST23 16-06-2015 Special Medical Unit 3 
BC-14-130 ST23 24-04-2014 Intensive Care Unit 
BC-14-31 ST23 24-01-2014 Surgical Unit 1 
BC-15-13 ST23 22-01-2015 Intensive Care Unit 
BC-15-55 ST3549-CC23 26-05-2015 Surgical Unit 1 
BC-15-45 ST3550-CC23 22-04-2015 Intensive Care Unit 
BC-14-197 ST36 05-07-2014 Intensive Care Unit 
BC-15-34 ST380 09-03-2015 Emergency Department 
BC-15-51 ST380 11-05-2015 Oncology Unit 1 
BC-14-298 ST65 08-10-2014 VIP Unit 
BC-14-95 ST714 21-03-2014 Intensive Care Unit 
BC-14-96 ST714 21-03-2014 Pediatric Intensive Care Unit 






3.7.2 The capsule type, string test positivity and the presence of siderophore genes 
 The capsule type, positivity in string test and the presence of various iron 
acquisition genes are shown in Table 21.   
Table 21: Capsule type, string test and iron acquisition genes of hvKP strains 
 
The string test was uniformly positive in all K1 capsule type strains and yielded 
varying results with the K2 isolates, but was negative with the other strains. The most 
common siderophore systems were present in all isolates, and the majority of them 









BC-15-61 ST23 K1 pos iucA, kfuBC, entB, iroB, irp2 
BC-14-130 ST23 K1 pos iucA, kfuBC, entB, iroB, irp2 
BC-14-31 ST23 K1 pos iucA, kfuBC, entB, iroB, irp2 








K1 pos iucA, kfuBC, entB, iroB, irp2 
BC-14-197 ST36 ND neg iucA, entB, iroB, irp2 
BC-15-34 ST380 K2 pos iucA, kfuBC, entB, iroB, irp2 
BC-15-51 ST380 K2 neg iucA, kfuBC, entB, iroB, irp2 
BC-14-298 ST65 K2 pos iucA, entB, iroB, irp2 
BC-14-95 ST714 ND neg iucA, entB, iroB, irp2 
BC-14-96 ST714 ND neg iucA, entB, iroB, irp2 






The comparative respective figures found in cKP strains are shown in Table 
22. While hvKP isolates carried as many as 4.53 ± 0.66 iron acquisition related genes 
per strains, the same figure among cKP was 1.94 ± 0.92, only. With the exception of 
enterobactin gene entB, present in all strains, all other iron acquisition related genes 
were significantly more common among hvKP isolates. Nevertheless, the only gene 
clearly distinguishing between the two group of strains was iroB, part of the 
salmochelin siderophore system.  
 
Table 22: Frequency of iron acquisition system genes and string test positivity 
among cKP and hvKP strains 
 
It was noteworthy that none of the String test positive cKP strains carried any 
iron acquisition related genes beyond the omni-present entB. 
 
 




Genes    
iucA 9.8 100.0 <0.0001 
kfuBC 30.4 61.5 0.0322 
entB 100.0 100.0 1.0 
iroB 0.0 100.0 <0.0001 
irp2 54.5 100.0 0.0008 
Feature    






3.7.3 The location of the rmpA gene  
 Studying the location of the rmpA gene in the hvKP isolates. Hybridizing the 
plasmid electrophoresis gel of the strains with a rmpA specific probe revealed that in 
all isolates the gene was located on plasmids of varying size, but all were large (>150 
kb) in size (Figure 13). 
 
 
Figure 13: Localization of the rmpA gene 39R861: Plasmid molecular weight 
standard 
 
3.7.4 Antimicrobial susceptibility of hypervirulent strains 
 Analysing the antimicrobial susceptibility of hvKP strains revealed that, in 
general, they were highly susceptible (Table 23). There was one single exception, a 
carbapenem resistant, i.e. CRKP, in which the highly virulent character was combined 
with an extensive resistance pattern. It was noteworthy, that despite its broad range of 
non-susceptibility (AMC, PTZ, FOX, CPD, CAZ, CTX, IMI, MEM, ERT, SXT, AK, 
TOB, DOX), this strain (BC-15-13) still exhibited susceptibility to colistin. On the 








The CR hvKP strain carried a blaVIM carbapenemase gene, which represented 
a new allele, VIM-55 (GenBank MG552720). 
 












































3.8 Characteristics of patients carrying hypervirulent Klebsiella pneumoniae 
 Patients suffering from hvKP infections were significantly more likely to have 
diabetes and were significantly less likely to have received previous antibiotic therapy. 
Although the frequency of being Emirati was considerably more common among 
patients with cKP infections, the difference did not reach statistical significance (Table 
24). 
Table 24: Comparison of patients’ characteristics with cKP and hvKP infections 
*     109 patients for whom data were available 
**    Student’s t test 
 
3.9 iucA positive but rmpA/A2 negative strains 
 Eleven strains, while carrying the iucA gene, were rmpA/A2 negative and 
hence, they did not qualify as hvKP. Nevertheless, they carried a broad panel of iron-
acquisition genes. The average number of such genes per strain was 3.90 ± 0.30 
compared to that seen in hvKP (4.53 ± 0.66), and much higher than seen in the 101 
iucA negative cKP strains (1.73 ± 0.69). With the exception of one ST502 isolate, they 
Gene / Feature 
% positivity Significance 
(P) cKP* hvKP 
Co-morbidities    
Diabetes 22.0 76.9 0.0001 
Malignancy 43.1 38.5 1.0 
Nationality    
Age 44.1 ± 33.45 55.6 ± 22.96 0.2116** 
Emirati 58.7 38.5 0.2367 
Antibiotic exposure    
Any antibiotics 57.8 23.1 0.0208 
Any beta-lactams 55.0 23.1 0.0807 






formed a single PFGE cluster (PF32) and represented ST231. These 10 strains were 
all carbapenem resistant carrying a blaOXA-232 gene and the rmtF 16S methylase gene. 
All of them exhibited a broad range of resistance, two of them being non-susceptible 
to colistin, too.  
 The time and location distribution of their isolation is shown in Table 14 (the 
























Chapter 4: Discussion 
 
During the two-year-long collection period 125 cases of Klebsiella 
pneumoniae bloodstream infection (BSI) were identified in our 461-bed tertiary care 
hospital. As most of the literature deals with MDR K. pneumoniae bloodstream 
infections, it is difficult to find general data on the incidence of K. pneumoniae BSI. 
Furthermore, even if data were available it is problematic to compare the incidence in 
variable clinical settings. Nevertheless, the rate of K. pneumoniae BSI during a two-
year-long period was high in our setting, if compared it to a 1420-bed tertiary-care 
teaching hospital in Northern Italy, where 217 unique patient K. pneumoniae BSIs 
were described during a same time-period (Girometti et al., 2014). This higher rate 
could possibly be explained by the fact that a large proportion of our patients suffered 
of either a solid tumour or of a haematological malignancy, and the BSI could have 
been the result of a mucosal barrier injury. It is especially plausible, as it has been 
shown that Klebsiella pneumoniae infections often originate from the patient’s own 
intestinal microbiota (Gorrie et al., 2017). Since our study was a retrospective 
investigation of K. pneumoniae isolated from bloodstream, unfortunately there is no 
data on the intestinal carriage of K. pneumoniae by these 125 patients to support this 
hypothesis. 
Of the 125 K. pneumoniae isolates 47 (37.6%) qualified as MDR using the 
European Centre for Disease Prevention and Control criteria (Magiorakos et al., 2012). 
This is a slightly higher figure than the one reported recently from South Korea 
(31.3%) (Kim et al., 2019), but substantially lower than the 64% reported from the 
above mentioned healthcare facility in Northern Italy (Girometti et al., 2014). The non-






47%, however, it is markedly higher than the South Korean CRKP rate (12% in our 
hospital vs. 3.1% in South Korea) (Girometti et al., 2014; Kim et al., 2019). It is 
noteworthy that prior antibiotic therapy was linked to the isolation of MDR K. 
pneumoniae.  Prior carbapenem therapy, on the other hand, was significantly linked to 
the isolation of a CRKP. Our findings confirm similar observations reported earlier 
from multiple geographical regions (Liu et al., 2018; Park et al., 2012). 
Despite the fact that K. pneumoniae, especially MDR K. pneumoniae, is prone 
to spread within the hospital settings (Hendrik et al., 2015), in this study the PFGE and 
MLST analysis has revealed a large variety of K. pneumoniae strains causing BSI, with 
only three clusters having >4 members exhibiting >80% similar PFGE patterns (Figure 
11). These results are suggestive of effective infection prevention and control program 
in our hospital. On the other hand, assuming that these K. pneumoniae strains likely 
originated from the patients’ own gastrointestinal tract (Gorrie et al., 2017), the 
findings also underline the importance of screening for colonisation of high risk 
patients.  
Revealing colonisation is especially important in the lights of the relatively 
high proportion of carbapenem resistant K. pneumoniae causing bloodstream 
infections, with predominance of OXA-232 producing K. pneumoniae ST231 carrying 
aerobactin, yersiniabactin and enterobactin siderophore genes. Carrying three or four 
siderophores was associated with being more virulent in a large study comparing 
virulence of K. pneumoniae (Holt et al., 2015), therefore the clonal spread of  
carbapenem resistant K. pneumoniae ST231, not only multidrug resistant but also 
virulent, is a serious concern. Although the K. pneumoniae ST231 clone is not 






reported to carry blaOXA-232 and to disseminate rapidly causing outbreaks in Brunei 
(Abdul Momin et al., 2017) and in India (Shankar et al., 2019). Sporadic OXA-232 
producing ST231 isolate was also reported from Switzerland (Mancini et al., 2018). 
As only limited time and location overlap was observed within this cluster of strains, 
such isolates were either repeatedly introduced into our institution or they had a 
common source yet to be revealed, but investigation of either of these hypotheses was 
beyond the scope of the study.  
The hypothesize is that this latter group of virulent and highly resistant isolates 
could also be considered as just being one step away to become really hypervirulent, 
i.e. by acquiring the plasmid-encoded rmpA/A2 genes. Only further surveillance work 
encountering ST231 hvKP otherwise closely related to these isolates could prove our 
assumption about the potential dangers of the evolvement of this highly resistant, 
hypervirulent variety. 
The other NDM and/or OXA-48-like producer isolates in the collection were 
diverse: OXA-232 or NDM-1 and OXA-232 co-producer ST14, OXA-162 producer 
ST307 and an NDM-1 producer ST70. The former two clonal lineages of K. 
pneumoniae are recognized as important international outbreaks clones (Navon-
Venezia et al., 2017), and both has been described already from the UAE to produce 
NDM-1 or OXA-48-like carbapenemases, or co-produce these carbapenemases. (Al-
Baloushi et al., 2018; Moubareck et al., 2018; Mouftah et al., 2019; Sonnevend et al., 
2015). 
ST70 is not considered a high-risk epidemic clone, however it was reported to 
carry blaCTX-M-type ESBL gene in Bulgaria (Markovska et al., 2017), blaKPC-2 in 






blaNDM-1 in Greece (Politi et al., 2019). In all these reports K. pneumoniae ST70 
occurred sporadically, but the presence of this clone in South America, the Balkan and 
now in the Gulf Region shows its capability to acquire genes coding for broad 
spectrum beta-lactam hydrolysing genes including various carbapenemases.  
Isolates of the other larger PFGE cluster, PF27 (Table 15) belonged to ST29, 
ST711 and ST714, which are all part of the clonal complex CC29. Members of this 
clonal complex were described to be ESBL (Surgers et al., 2019), or carbapenemase 
producers OXA-48 (Uz Zaman et al., 2014), NDM-1 (Mukherjee et al., 2019), and 
also being hypermucoviscous and hypervirulent (Turton et al., 2019). This latter 
hypervirulent subtype of CC29 were reported to have K54 capsular serotype. In our 
collection two K. pneumoniae ST714 isolates of this clonal group possessed rmpA/A2, 
salmochelin, aerobactin and yersiniabactin, but PCR for the K54 serotype did not 
detect the relevant gene, and the isolates were not hypermucoviscous by string test. 
Despite of these facts, these two isolates were considered hypervirulent based on their 
genotypes as suggested by Russo and Marr (2019). The hypervirulent ST714-CC29 
isolates remained susceptible to 3rd generation cephalosporins, but other members of 
the group with ST29 and ST711 were ESBL producers and carried the blaCTX-M gene. 
Consequently, although PFGE clustered these isolates, they were rather heterogenous. 
Even though, OXA-48 carbapenemase ST29 isolates were reported to cause outbreak 
in the region (Zaman et al., 2014), in our collection all CC29 isolate remained 
susceptible to carbapenems.  
The third large PFGE cluster, PF28 also contained several isolates with 
different sequence types (Table 15), further confirming the heterogeneity of our K. 






nine isolates belonged to ST23 or its single locus variants ST3549 and ST3550. These 
two sequence types were novel, first reported by us. ST23, or rather the clonal complex 
CC23 is considered as the prototype of hypervirulent K. pneumoniae. (Wyres et al., 
2019) Indeed, these 5 isolates of PF28 cluster harboured the rmpA/A2, salmochelin, 
aerobactin and yersiniabactin genes, had K1 serotype and were phenotypically 
hypermucoviscous (Table 21). In addition to these CC23 isolates, identified a further 
string test positive, genotypically hypervirulent K. pneumoniae ST23 with capsular 
type K1, exhibiting a slightly different PFGE profile. Of the six CC23 isolate five were 
susceptible to all of the antibiotics tested, but one isolate BC-15-13 was resistant to 3rd 
generation cephalosporin, carbapenem, co-trimoxazole, amikacin, tobramycin, 
tetracycline and chloramphenicol. BC15-13 carried a novel VIM allele by PCR and 
sequencing: VIM-55. This allele differs from VIM-19 by one amino acid, at position 
229 in VIM-55 an arginine replaces the histidine found in VIM-19. Exploring the 
genetic support and hydrolytic activity of this novel enzyme was beyond the scope of 
my research, further ongoing studies should reveal these features. Carbapenemase 
producer K. pneumoniae ST23 is a rare finding, although two members of the clone 
were reported to produce OXA-48 or NDM-1 from the United Kingdom (Turton et al., 
2018) (Roulston et al., 2018). VIM-producing members of the clone were only recently 
encountered in China (blaVIM-1) (Dong et al., 2019) and in Iran (blaVIM-2). (Mohammad 
et al., 2018) Nevertheless, finding of an isolate, which is MDR and hypervirulent is a 
most feared scenario, as such bacteria are truly “superbugs”, with a great capacity to 
cause disease and at the same time being extremely difficult to treat.  
 Further to identifying hypervirulent K. pneumoniae of the CC23 and CC29, it 






ST86, all possessing rmpA on plasmid, four siderophore genes, and all but the ST36 
isolate having capsular type K2 (Table 21). 
 K. pneumoniae ST36  has been reported to be present in several continents, is 
a known hvKP causing bacteremia, and it has also been reported to produce KPC-2 
from China. (Feng et al., 2018) Our ST36 isolate was non-susceptible to piperacillin-
tazobactam, to 3rd generation cephalosporins and to monobactams, but remained 
susceptible to carbapenems and non-beta-lactam antibiotics.  
The predominant serotype K2 hypervirulent clones K. pneumoniae  clones are 
the ST65, ST86, and ST380 (Bialek-Davenet et al., 2014), and members of all of these 
three clones were present and caused bloodstream infection in our institution. Isolates 
belonging to these clones were susceptible to antibiotics, i.e. they were typical hvKP. 
Hypervirulent K. pneumoniae infection, commonly encountered in the Pacific 
Rim of Asia and in China (Paczosa and Mecsas, 2016), has only been sporadically 
reported from the Gulf region. A few cases of infections caused by hypermucoviscous 
K. pneumoniae were reported from Saudi Arabia (Enani and El-Khizzi, 2012) and 
Oman (Basu et al., 2009), without any molecular characterization. Therefore, to the 
best of our knowledge, our observation is the first in the region describing hvKP strains 
causing bloodstream infections. It is noteworthy, that like the majority of cKP, the 
hvKP isolates were also diverse. 
In line with the earlier observations (Li et al., 2018; Russo and Marr, 2019), 
patients with diabetes, and those who did not received antibiotic therapy prior to the 
bloodstream infection were significantly more likely to suffer of an hvKP infection in 






ability of such strains to cause metastatic abscesses (Russo and Marr, 2019), no clinical 
information on metastatic infections, e.g. endophtalmitis, meningitis or liver abscess, 
neither on the 30-day-mortality were available to us. 
Defining hvKP is still a controversial issue, and the approach followed in our 
study by relying only on the genomic definition is widely accepted (Li et al., 2018). 
Further studies to complement our findings should confirm our, genomic definition of 
hypervirulence by performing in vivo studies. However, genetically hypervirulent 
isolates did not always exhibit full virulence in in vivo (Fu et al., 2019) but surmised 
the virulence potential of the isolates’ as all of them caused an invasive infection, i.e. 




















Chapter 5: Conclusions 
 
The majority of K. pneumoniae isolated from the two-year-long study period 
exhibited diverse molecular fingerprints.  More than a third of the isolates were multi-
drug resistant, and isolation of an MDR K. pneumoniae infection was more likely if 
the patient had previous exposure to antibiotics.  High carbapenem resistance rate was 
detected with the predominance of OXA-232 producing K. pneumoniae ST231. Over 
10% of the collection was hypervirulent K. pneumoniae based on genomic definition, 
i.e. the presence of plasmid-borne rmpA, salmochelin, aerobactin and yersiniabactin 
genes. The hypervirulent isolates were also diverse, belonging to ST23, ST3549, 
ST3550, ST36, ST380, ST65, ST714 and ST86. The presence of ST231 CRKP strains 
carrying the siderophore genes otherwise characteristic to hvKP, but lacking the 
rmpA/A2 gene needs further attention as, at least theoretically, the mere acquisition of 
a plasmid carrying the rmpA/A2 gene could convert these highly resistant strains to 
real hvKP. Diabetic patients and those who did not receive prior antibiotic therapy 
were more likely to have hypervirulent K. pneumoniae infection. The majority of 
hypervirulent K. pneumoniae were susceptible to antibiotics, however an ST23 isolate 
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